



Study Report C1-003

Appendix - Tables

27/03/2023

Version 3.1

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
		Dissemination level: Public

TABLE OF CONTENTS

Table of contents	2
Table 1 – Overall incidence of Antibiotics from the WHO Watch list	3
Table 2– Antibiotic subclass and individual antibiotics from the WHO Watch list	24
Table 3– Duration of Antibiotic drug use of top 5 of most prescribed antibiotics per database	28
Table 4– Indication of use (in terms of infections) of top 5 of most prescribed antibiotics per database.....	31
Table 5– Top 10 of disease codes reported at time of prescribing of top 5 of most prescribed antibiotics per database	45


	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
		Dissemination level: Public

TABLE 1 – OVERALL INCIDENCE OF ANTIBIOTICS FROM THE WHO WATCH LIST

n_persons	person_years	n_prescriptions	CPRD GOLD	
			incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
8,215,316	36,146,126	NA	NA (NA to NA)	Arbekacin (J01GB12)
8,215,316	36,146,126	NA	NA (NA to NA)	Aspoxicillin (J01CA19)
8,214,698	36,114,808	130,553	361 (359 to 363)	Azithromycin (J01FA10)
8,215,316	36,146,126	NA	NA (NA to NA)	Azlocillin (J01CA09)
8,215,316	36,146,126	NA	NA (NA to NA)	Beknamycin (J01GB13)
8,215,316	36,146,126	NA	NA (NA to NA)	Biapenem (J01DH05)
8,215,316	36,146,126	NA	NA (NA to NA)	Carbenicillin (J01CA03)
8,215,316	36,146,126	NA	NA (NA to NA)	Carindacillin (J01CA05)
8,215,301	36,144,296	15,857	43 (43 to 44)	Cefaclor (J01DC04)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefamandole (J01DC03)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefbuperazone (J01DC13)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefcapene-pivoxil (J01DD17)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefdinir (J01DD15)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefepime (J01DE01)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefetamet-pivoxil (J01DD10)
8,215,313	36,145,947	1,567	4 (4 to 4)	Cefixime (J01DD08)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefmenoxime (J01DD05)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefmetazole (J01DC09)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefminox (J01DC12)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefodizime (J01DD09)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefonicid (J01DC06)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefoperazone (J01DD12)
8,215,316	36,146,126	NA	NA (NA to NA)	Ceforanide (J01DC11)
8,215,316	36,146,117	85	0 (0 to 0)	Cefotaxime (J01DD01)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefotetan (J01DC05)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefotiam (J01DC07)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefoxitin (J01DC01)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefozopran (J01DE03)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefpiramide (J01DD11)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefpirome (J01DE02)
8,215,316	36,146,122	35	0 (0 to 0)	Cefpodoxime-proxetil (J01DD13)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefprozil (J01DC10)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefsulodin (J01DD03)
8,215,316	36,146,108	101	0 (0 to 0)	Ceftazidime (J01DD02)
8,215,316	36,146,126	NA	NA (NA to NA)	Cefteram-pivoxil (J01DD18)
8,215,316	36,146,126	NA	NA (NA to NA)	Ceftibuten (J01DD14)
8,215,316	36,146,126	NA	NA (NA to NA)	Ceftizoxime (J01DD07)

CPRD GOLD				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
8,215,316	36,146,027	992	2 (2 to 2)	Ceftriaxone (J01DD04)
8,215,309	36,145,569	4,640	12 (12 to 13)	Cefuroxime (J01DC02)
8,215,316	36,146,126	NA	NA (NA to NA)	Chlortetracycline (J01AA03)
8,215,316	36,146,126	NA	NA (NA to NA)	Cinoxacin (J01MB06)
8,215,160	36,105,699	369,519	1,023 (1,020 to 1,026)	Ciprofloxacin (J01MA02)
8,214,946	36,008,884	1,288,110	3,577 (3,571 to 3,583)	Clarithromycin (J01FA09)
8,215,316	36,146,126	NA	NA (NA to NA)	Clofocetol (J01XX03)
8,215,316	36,146,126	NA	NA (NA to NA)	Clomocycline (J01AA11)
8,215,316	36,146,126	NA	NA (NA to NA)	Delafloxacin (J01MA23)
8,215,278	36,145,738	798	2 (2 to 2)	Demeclocycline (J01AA01)
8,215,316	36,146,126	NA	NA (NA to NA)	Dibekacin (J01GB09)
8,215,316	36,146,126	NA	NA (NA to NA)	Dirithromycin (J01FA13)
8,215,316	36,146,126	NA	NA (NA to NA)	Doripenem (J01DH04)
8,215,316	36,146,126	NA	NA (NA to NA)	Enoxacin (J01MA04)
8,215,316	36,146,109	174	0 (0 to 0)	Ertapenem (J01DH03)
8,214,904	36,058,004	747,601	2,073 (2,068 to 2,078)	Erythromycin (J01FA01)
8,215,316	36,146,114	77	0 (0 to 0)	Fidaxomicin (A07AA12)
8,215,316	36,146,126	NA	NA (NA to NA)	Fleroxacin (J01MA08)
8,215,316	36,146,126	NA	NA (NA to NA)	Flomoxef (J01DC14)
8,215,316	36,146,126	NA	NA (NA to NA)	Flumequine (J01MB07)
8,215,316	36,146,126	NA	NA (NA to NA)	Flurithromycin (J01FA14)
8,215,313	36,145,142	11,222	31 (30 to 31)	Fosfomycin (J01XX01)
8,215,308	36,145,732	2,235	6 (5 to 6)	Fusidic-acid (J01XC01)
8,215,316	36,146,126	NA	NA (NA to NA)	Garenoxacin (J01MA19)
8,215,316	36,146,126	NA	NA (NA to NA)	Gatifloxacin (J01MA16)
8,215,316	36,146,126	NA	NA (NA to NA)	Gemifloxacin (J01MA15)
8,215,316	36,146,126	NA	NA (NA to NA)	Grepafloxacin (J01MA11)
8,215,316	36,146,126	NA	NA (NA to NA)	Imipenem_cilastatin (J01DH51)
8,215,316	36,146,126	NA	NA (NA to NA)	Isepamicin (J01GB11)
8,215,316	36,146,126	NA	NA (NA to NA)	Josamycin (J01FA07)
8,215,316	36,146,126	NA	NA (NA to NA)	Kanamycin (A07AA08, J01GB04)
8,215,316	36,146,126	NA	NA (NA to NA)	Lascufloxacin (J01MA25)
8,215,316	36,146,126	NA	NA (NA to NA)	Latamoxef (J01DD06)
8,215,311	36,144,871	10,593	29 (28 to 29)	Levofloxacin (J01MA12)
8,215,316	36,146,126	NA	NA (NA to NA)	Levonadifloxacin (J01MA24)
8,215,316	36,146,126	NA	NA (NA to NA)	Lincomycin (J01FF02)
8,215,316	36,146,126	NA	NA (NA to NA)	Lomefloxacin (J01MA07)
8,215,316	36,146,126	NA	NA (NA to NA)	Loracarbef (J01DC08)
8,214,244	36,032,802	313,052	868 (865 to 871)	Lymecycline (J01AA04)
8,215,316	36,146,092	134	0 (0 to 0)	Meropenem (J01DH02)

CPRD GOLD				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
8,215,316	36,146,126	NA	NA (NA to NA)	Metacycline (J01AA05)
8,215,316	36,146,126	NA	NA (NA to NA)	Mezlocillin (J01CA10)
8,215,316	36,146,126	NA	NA (NA to NA)	Midecamycin (J01FA03)
8,215,195	36,137,931	17,625	48 (48 to 49)	Minocycline (J01AA08)
8,215,316	36,146,126	NA	NA (NA to NA)	Miocamycin (J01FA11)
8,215,313	36,145,919	1,700	4 (4 to 4)	Moxifloxacin (J01MA14)
8,215,316	36,146,126	NA	NA (NA to NA)	Nemonoxacin (J01MB08)
8,215,311	36,146,024	539	1 (1 to 1)	Neomycin (A07AA01, J01GB05)
8,215,316	36,146,126	NA	NA (NA to NA)	Netilmicin (J01GB07)
8,215,309	36,145,788	2,186	6 (5 to 6)	Norfloxacin (J01MA06)
8,215,304	36,142,765	26,405	73 (72 to 73)	Ofloxacin (J01MA01)
8,215,316	36,146,126	NA	NA (NA to NA)	Oleandomycin (J01FA05)
8,215,316	36,146,126	NA	NA (NA to NA)	Oxolinic-acid (J01MB05)
8,214,718	36,094,848	187,002	518 (515 to 520)	Oxytetracycline (J01AA06)
8,215,316	36,146,126	NA	NA (NA to NA)	Panipenem (J01DH55)
8,215,316	36,146,126	NA	NA (NA to NA)	Pazufloxacin (J01MA18)
8,215,316	36,146,126	NA	NA (NA to NA)	Pefloxacin (J01MA03)
8,215,316	36,146,126	NA	NA (NA to NA)	Pheneticillin (J01CE05)
8,215,316	36,146,126	NA	NA (NA to NA)	Pipemidic-acid (J01MB04)
8,215,316	36,146,126	NA	NA (NA to NA)	Piperacillin (J01CA12)
8,215,315	36,146,107	119	0 (0 to 0)	Piperacillin_tazobactam (J01CR05, J01CA12)
8,215,316	36,146,126	NA	NA (NA to NA)	Piromidic-acid (J01MB03)
8,215,316	36,146,123	NA	NA (NA to NA)	Pristinamycin (J01FG01)
8,215,316	36,146,126	NA	NA (NA to NA)	Prulifloxacin (J01MA17)
8,215,316	36,146,126	NA	NA (NA to NA)	Ribostamycin (J01GB10)
8,215,316	36,146,115	38	0 (0 to 0)	Rifabutin (J04AB04)
8,215,288	36,144,326	6,594	18 (17 to 18)	Rifampicin (J04AB02)
8,215,316	36,146,126	NA	NA (NA to NA)	Rifamycin (A07AA13, J04AB03)
8,215,276	36,144,870	1,881	5 (4 to 5)	Rifaximin (A07AA11)
8,215,316	36,146,126	NA	NA (NA to NA)	Rokitamycin (J01FA12)
8,215,316	36,146,126	NA	NA (NA to NA)	Rolitetracycline (J01AA09)
8,215,316	36,146,126	NA	NA (NA to NA)	Rosoxacin (J01MB01)
8,215,316	36,146,126	NA	NA (NA to NA)	Roxithromycin (J01FA06)
8,215,316	36,146,126	NA	NA (NA to NA)	Rufloxacin (J01MA10)
8,215,316	36,146,126	NA	NA (NA to NA)	Sarecycline (J01AA14)
8,215,316	36,146,126	NA	NA (NA to NA)	Sisomicin (J01GB08)
8,215,316	36,146,126	NA	NA (NA to NA)	Sitafloxacin (J01MA21)
8,215,316	36,146,126	NA	NA (NA to NA)	Solithromycin (J01FA16)
8,215,316	36,146,126	NA	NA (NA to NA)	Sparfloxacin (J01MA09)
8,215,316	36,146,126	NA	NA (NA to NA)	Spiramycin (J01FA02)

CPRD GOLD				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
8,215,316	36,146,126	NA	NA (NA to NA)	Streptoduocin (J01GA02)
8,215,316	36,146,126	NA	NA (NA to NA)	Streptomycin (A07AA04, J01GA01)
8,215,316	36,146,126	NA	NA (NA to NA)	Sulbenicillin (J01CA16)
8,215,316	36,146,126	NA	NA (NA to NA)	Tazobactam (J01CG02)
8,215,316	36,146,126	NA	NA (NA to NA)	Tebipenem (J01DH06)
8,215,316	36,146,103	225	0 (0 to 0)	Teicoplanin (J01XA02)
8,215,316	36,146,125	NA	NA (NA to NA)	Telithromycin (J01FA15)
8,215,316	36,146,126	NA	NA (NA to NA)	Temafloxacin (J01MA05)
8,215,316	36,146,125	NA	NA (NA to NA)	Temocillin (J01CA17)
8,215,316	36,146,126	NA	NA (NA to NA)	Ticarcillin (J01CA13)
8,215,316	36,146,102	86	0 (0 to 0)	Tobramycin (J01GB01)
8,215,316	36,146,126	NA	NA (NA to NA)	Tosufloxacin (J01MA22)
8,215,316	36,146,126	NA	NA (NA to NA)	Troleandomycin (J01FA08)
8,215,316	36,146,126	NA	NA (NA to NA)	Trovafloracin (J01MA13)
8,215,313	36,145,950	1,360	3 (3 to 3)	Vancomycin (A07AA09, J01XA01)

IPCI				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
2,283,830	10,291,198	NA	NA (NA to NA)	Arbekacin (J01GB12)
2,283,830	10,291,198	NA	NA (NA to NA)	Aspoxicillin (J01CA19)
2,283,523	10,267,032	191,182	1,862 (1,853 to 1,870)	Azithromycin (J01FA10)
2,283,830	10,291,198	NA	NA (NA to NA)	Azlocillin (J01CA09)
2,283,830	10,291,198	NA	NA (NA to NA)	Bekanamycin (J01GB13)
2,283,830	10,291,198	NA	NA (NA to NA)	Biapenem (J01DH05)
2,283,830	10,291,198	NA	NA (NA to NA)	Carbenicillin (J01CA03)
2,283,830	10,291,198	NA	NA (NA to NA)	Carindacillin (J01CA05)
2,283,829	10,291,097	839	8 (7 to 8)	Cefaclor (J01DC04)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefamandole (J01DC03)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefbuperazone (J01DC13)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefcapene-pivoxil (J01DD17)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefdinir (J01DD15)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefepime (J01DE01)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefetamet-pivoxil (J01DD10)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefixime (J01DD08)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefmenoxime (J01DD05)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefmetazole (J01DC09)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefminox (J01DC12)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefodizime (J01DD09)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefonicid (J01DC06)

IPCI				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefoperazone (J01DD12)
2,283,830	10,291,198	NA	NA (NA to NA)	Ceforanide (J01DC11)
2,283,830	10,291,177	171	1 (1 to 1)	Cefotaxime (J01DD01)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefotetan (J01DC05)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefotiam (J01DC07)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefoxitin (J01DC01)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefozopran (J01DE03)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefpiramide (J01DD11)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefpirome (J01DE02)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefpodoxime-proxetil (J01DD13)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefprozil (J01DC10)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefsulodin (J01DD03)
2,283,829	10,291,166	181	1 (1 to 2)	Ceftazidime (J01DD02)
2,283,830	10,291,198	NA	NA (NA to NA)	Cefteram-pivoxil (J01DD18)
2,283,830	10,291,158	316	3 (2 to 3)	Ceftibuten (J01DD14)
2,283,830	10,291,198	NA	NA (NA to NA)	Ceftizoxime (J01DD07)
2,283,825	10,290,604	4,046	39 (38 to 40)	Ceftriaxone (J01DD04)
2,283,827	10,290,957	1,816	17 (16 to 18)	Cefuroxime (J01DC02)
2,283,830	10,291,198	NA	NA (NA to NA)	Chlortetracycline (J01AA03)
2,283,830	10,291,198	NA	NA (NA to NA)	Cinoxacin (J01MB06)
2,283,789	10,274,580	150,313	1,462 (1,455 to 1,470)	Ciprofloxacin (J01MA02)
2,283,798	10,281,531	85,183	828 (822 to 834)	Clarithromycin (J01FA09)
2,283,830	10,291,198	NA	NA (NA to NA)	Clofoctol (J01XX03)
2,283,830	10,291,198	NA	NA (NA to NA)	Clomocycline (J01AA11)
2,283,830	10,291,198	NA	NA (NA to NA)	Delafloxacin (J01MA23)
2,283,830	10,291,192	21	0 (0 to 0)	Demeclocycline (J01AA01)
2,283,830	10,291,198	NA	NA (NA to NA)	Dibekacin (J01GB09)
2,283,830	10,291,198	NA	NA (NA to NA)	Dirithromycin (J01FA13)
2,283,830	10,291,198	NA	NA (NA to NA)	Doripenem (J01DH04)
2,283,830	10,291,198	NA	NA (NA to NA)	Enoxacin (J01MA04)
2,283,830	10,291,196	15	0 (0 to 0)	Ertapenem (J01DH03)
2,283,817	10,289,762	10,527	102 (100 to 104)	Erythromycin (J01FA01)
2,283,830	10,291,195	23	0 (0 to 0)	Fidaxomicin (A07AA12)
2,283,830	10,291,198	NA	NA (NA to NA)	Fleroxacin (J01MA08)
2,283,830	10,291,198	NA	NA (NA to NA)	Flomoxef (J01DC14)
2,283,830	10,291,198	NA	NA (NA to NA)	Flumequine (J01MB07)
2,283,830	10,291,181	104	1 (0 to 1)	Flurithromycin (J01FA14)
2,283,811	10,279,502	122,406	1,190 (1,184 to 1,197)	Fosfomycin (J01XX01)
2,283,830	10,291,183	101	0 (0 to 1)	Fusidic-acid (J01XC01)
2,283,830	10,291,198	NA	NA (NA to NA)	Garenoxacin (J01MA19)

IPCI				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
2,283,830	10,291,198	NA	NA (NA to NA)	Gatifloxacin (J01MA16)
2,283,830	10,291,198	NA	NA (NA to NA)	Gemifloxacin (J01MA15)
2,283,830	10,291,198	NA	NA (NA to NA)	Grepafloxacin (J01MA11)
2,283,830	10,291,197	NA	NA (NA to NA)	Imipenem_cilastatin (J01DH51)
2,283,830	10,291,198	NA	NA (NA to NA)	Isepamicin (J01GB11)
2,283,830	10,291,198	NA	NA (NA to NA)	Josamycin (J01FA07)
2,283,830	10,291,198	NA	NA (NA to NA)	Kanamycin (A07AA08, J01GB04)
2,283,830	10,291,198	NA	NA (NA to NA)	Lascufloxacin (J01MA25)
2,283,830	10,291,198	NA	NA (NA to NA)	Latamoxef (J01DD06)
2,283,827	10,290,174	8,211	79 (78 to 81)	Levofloxacin (J01MA12)
2,283,830	10,291,198	NA	NA (NA to NA)	Levonadifloxacin (J01MA24)
2,283,830	10,291,198	NA	NA (NA to NA)	Lincomycin (J01FF02)
2,283,830	10,291,198	NA	NA (NA to NA)	Lomefloxacin (J01MA07)
2,283,830	10,291,198	NA	NA (NA to NA)	Loracarbef (J01DC08)
2,283,830	10,291,198	NA	NA (NA to NA)	Lymecycline (J01AA04)
2,283,829	10,291,175	136	1 (1 to 1)	Meropenem (J01DH02)
2,283,830	10,291,198	NA	NA (NA to NA)	Metacycline (J01AA05)
2,283,830	10,291,198	NA	NA (NA to NA)	Mezlocillin (J01CA10)
2,283,830	10,291,198	NA	NA (NA to NA)	Midecamycin (J01FA03)
2,283,753	10,285,290	21,289	206 (204 to 209)	Minocycline (J01AA08)
2,283,830	10,291,198	NA	NA (NA to NA)	Miocamycin (J01FA11)
2,283,828	10,290,726	4,168	40 (39 to 41)	Moxifloxacin (J01MA14)
2,283,830	10,291,198	NA	NA (NA to NA)	Nemonoxacin (J01MB08)
2,283,830	10,291,189	58	0 (0 to 0)	Neomycin (A07AA01, J01GB05)
2,283,830	10,291,198	NA	NA (NA to NA)	Netilmicin (J01GB07)
2,283,804	10,289,089	16,074	156 (153 to 158)	Norfloxacin (J01MA06)
2,283,829	10,290,537	5,276	51 (49 to 52)	Ofloxacin (J01MA01)
2,283,830	10,291,198	NA	NA (NA to NA)	Oleandomycin (J01FA05)
2,283,830	10,291,198	NA	NA (NA to NA)	Oxolinic-acid (J01MB05)
2,283,827	10,288,882	14,624	142 (139 to 144)	Oxytetracycline (J01AA06)
2,283,830	10,291,198	NA	NA (NA to NA)	Panipenem (J01DH55)
2,283,830	10,291,198	NA	NA (NA to NA)	Pazufloxacin (J01MA18)
2,283,830	10,291,198	NA	NA (NA to NA)	Pefloxacin (J01MA03)
2,283,814	10,285,437	53,197	517 (512 to 521)	Pheneticillin (J01CE05)
2,283,829	10,291,155	253	2 (2 to 2)	Pipemidic-acid (J01MB04)
2,283,830	10,291,195	20	0 (0 to 0)	Piperacillin (J01CA12)
2,283,830	10,291,194	27	0 (0 to 0)	Piperacillin_tazobactam (J01CR05, J01CA12)
2,283,830	10,291,198	NA	NA (NA to NA)	Piromidic-acid (J01MB03)
2,283,830	10,291,198	NA	NA (NA to NA)	Pristinamycin (J01FG01)
2,283,830	10,291,198	NA	NA (NA to NA)	Prulifloxacin (J01MA17)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1 Dissemination level: Public

IPCI				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
2,283,830	10,291,198	NA	NA (NA to NA)	Ribostamycin (J01GB10)
2,283,830	10,291,193	17	0 (0 to 0)	Rifabutin (J04AB04)
2,283,824	10,290,615	2,271	22 (21 to 22)	Rifampicin (J04AB02)
2,283,830	10,291,198	NA	NA (NA to NA)	Rifamycin (A07AA13, J04AB03)
2,283,823	10,291,072	227	2 (1 to 2)	Rifaximin (A07AA11)
2,283,830	10,291,198	NA	NA (NA to NA)	Rokitamycin (J01FA12)
2,283,830	10,291,198	NA	NA (NA to NA)	Rolitetracycline (J01AA09)
2,283,830	10,291,198	NA	NA (NA to NA)	Rosoxacin (J01MB01)
2,283,830	10,291,069	1,271	12 (11 to 13)	Roxithromycin (J01FA06)
2,283,830	10,291,198	NA	NA (NA to NA)	Rufloxacin (J01MA10)
2,283,830	10,291,198	NA	NA (NA to NA)	Sarecycline (J01AA14)
2,283,830	10,291,198	NA	NA (NA to NA)	Sisomicin (J01GB08)
2,283,830	10,291,198	NA	NA (NA to NA)	Sitafloxacin (J01MA21)
2,283,830	10,291,198	NA	NA (NA to NA)	Solithromycin (J01FA16)
2,283,830	10,291,198	NA	NA (NA to NA)	Sparfloxacin (J01MA09)
2,283,830	10,291,198	NA	NA (NA to NA)	Spiramycin (J01FA02)
2,283,830	10,291,198	NA	NA (NA to NA)	Streptoduocin (J01GA02)
2,283,830	10,291,198	NA	NA (NA to NA)	Streptomycin (A07AA04, J01GA01)
2,283,830	10,291,198	NA	NA (NA to NA)	Sulbenicillin (J01CA16)
2,283,830	10,291,198	NA	NA (NA to NA)	Tazobactam (J01CG02)
2,283,830	10,291,198	NA	NA (NA to NA)	Tebipenem (J01DH06)
2,283,830	10,291,197	6	0 (0 to 0)	Teicoplanin (J01XA02)
2,283,830	10,291,198	NA	NA (NA to NA)	Telithromycin (J01FA15)
2,283,830	10,291,198	NA	NA (NA to NA)	Temafloxacin (J01MA05)
2,283,830	10,291,198	NA	NA (NA to NA)	Temocillin (J01CA17)
2,283,830	10,291,198	NA	NA (NA to NA)	Ticarcillin (J01CA13)
2,283,828	10,291,174	157	1 (1 to 1)	Tobramycin (J01GB01)
2,283,830	10,291,198	NA	NA (NA to NA)	Tosufloxacin (J01MA22)
2,283,830	10,291,198	NA	NA (NA to NA)	Troleandomycin (J01FA08)
2,283,830	10,291,198	NA	NA (NA to NA)	Trovafloxacin (J01MA13)
2,283,830	10,291,123	394	3 (3 to 4)	Vancomycin (A07AA09, J01XA01)

IQVIA Germany				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
14,854,799	68,782,738	NA	NA (NA to NA)	Arbekacin (J01GB12)
14,854,799	68,782,738	NA	NA (NA to NA)	Aspoxicillin (J01CA19)
14,853,228	68,721,284	674,434	981 (979 to 983)	Azithromycin (J01FA10)
14,854,799	68,782,738	NA	NA (NA to NA)	Azlocillin (J01CA09)

IQVIA Germany				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
14,854,799	68,782,738	NA	NA (NA to NA)	Bekanamycin (J01GB13)
14,854,799	68,782,738	NA	NA (NA to NA)	Biapenem (J01DH05)
14,854,799	68,782,738	NA	NA (NA to NA)	Carbencillin (J01CA03)
14,854,799	68,782,738	NA	NA (NA to NA)	Carindacillin (J01CA05)
14,854,447	68,748,033	369,028	536 (535 to 538)	Cefaclor (J01DC04)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefamandole (J01DC03)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefbuperazone (J01DC13)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefcapene-pivoxil (J01DD17)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefdinir (J01DD15)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefditoren-pivoxil (J01DD16)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefepime (J01DE01)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefetamet-pivoxil (J01DD10)
14,854,730	68,775,566	72,410	105 (104 to 106)	Cefixime (J01DD08)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefmenoxime (J01DD05)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefmetazole (J01DC09)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefminox (J01DC12)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefodizime (J01DD09)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefonicid (J01DC06)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefoperazone (J01DD12)
14,854,799	68,782,738	NA	NA (NA to NA)	Ceforanide (J01DC11)
14,854,799	68,782,724	143	0 (0 to 0)	Cefotaxime (J01DD01)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefotetan (J01DC05)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefotiam (J01DC07)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefoxitin (J01DC01)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefozopran (J01DE03)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefpiramide (J01DD11)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefpirome (J01DE02)
14,854,646	68,763,834	196,232	285 (284 to 286)	Cefpodoxime-proxetil (J01DD13)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefprozil (J01DC10)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefsulodin (J01DD03)
14,854,799	68,782,723	135	0 (0 to 0)	Ceftazidime (J01DD02)
14,854,799	68,782,738	NA	NA (NA to NA)	Cefteram-pivoxil (J01DD18)
14,854,780	68,780,949	17,588	25 (25 to 25)	Ceftibuten (J01DD14)
14,854,799	68,782,738	NA	NA (NA to NA)	Ceftizoxime (J01DD07)
14,854,796	68,782,451	2,851	4 (3 to 4)	Ceftriaxone (J01DD04)
14,854,106	68,692,068	929,283	1,352 (1,350 to 1,355)	Cefuroxime (J01DC02)
14,854,799	68,782,738	NA	NA (NA to NA)	Chlortetracycline (J01AA03)

IQVIA Germany				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
14,854,799	68,782,738	NA	NA (NA to NA)	Cinoxacin (J01MB06)
14,854,411	68,715,816	676,750	984 (982 to 987)	Ciprofloxacin (J01MA02)
14,854,595	68,750,621	329,182	478 (477 to 480)	Clarithromycin (J01FA09)
14,854,799	68,782,738	NA	NA (NA to NA)	Clofoctol (J01XX03)
14,854,799	68,782,738	NA	NA (NA to NA)	Clomocycline (J01AA11)
14,854,799	68,782,738	NA	NA (NA to NA)	Delafloxacin (J01MA23)
14,854,799	68,782,737	5	0 (0 to 0)	Demeclocycline (J01AA01)
14,854,799	68,782,738	NA	NA (NA to NA)	Dibekacin (J01GB09)
14,854,799	68,782,738	NA	NA (NA to NA)	Dirithromycin (J01FA13)
14,854,799	68,782,738	NA	NA (NA to NA)	Doripenem (J01DH04)
14,854,794	68,782,319	4,402	6 (6 to 6)	Enoxacin (J01MA04)
14,854,799	68,782,726	108	0 (0 to 0)	Ertapenem (J01DH03)
14,854,469	68,763,770	136,691	198 (197 to 199)	Erythromycin (J01FA01)
14,854,798	68,782,722	143	0 (0 to 0)	Fidaxomicin (A07AA12)
14,854,799	68,782,738	NA	NA (NA to NA)	Fleroxacin (J01MA08)
14,854,799	68,782,738	NA	NA (NA to NA)	Flomoxef (J01DC14)
14,854,799	68,782,738	NA	NA (NA to NA)	Flumequine (J01MB07)
14,854,799	68,782,738	NA	NA (NA to NA)	Flurithromycin (J01FA14)
14,854,682	68,750,681	403,757	587 (585 to 589)	Fosfomycin (J01XX01)
14,854,799	68,782,738	NA	NA (NA to NA)	Fusidic-acid (J01XC01)
14,854,799	68,782,738	NA	NA (NA to NA)	Garenoxacin (J01MA19)
14,854,799	68,782,738	NA	NA (NA to NA)	Gatifloxacin (J01MA16)
14,854,799	68,782,738	NA	NA (NA to NA)	Gemifloxacin (J01MA15)
14,854,799	68,782,738	NA	NA (NA to NA)	Grepafloxacin (J01MA11)
14,854,799	68,782,728	62	0 (0 to 0)	Imipenem_cilastatin (J01DH51)
14,854,799	68,782,738	NA	NA (NA to NA)	Isepamicin (J01GB11)
14,854,799	68,782,738	NA	NA (NA to NA)	Josamycin (J01FA07)
14,854,634	68,767,338	97,035	141 (140 to 141)	Kanamycin (A07AA08, J01GB04)
14,854,799	68,782,738	NA	NA (NA to NA)	Lasclufloxacin (J01MA25)
14,854,799	68,782,738	NA	NA (NA to NA)	Latamoxef (J01DD06)
14,854,651	68,760,077	224,036	325 (324 to 327)	Levofloxacin (J01MA12)
14,854,799	68,782,738	NA	NA (NA to NA)	Levonadifloxacin (J01MA24)
14,854,799	68,782,738	NA	NA (NA to NA)	Lincomycin (J01FF02)
14,854,799	68,782,738	NA	NA (NA to NA)	Lomefloxacin (J01MA07)
14,854,799	68,782,738	NA	NA (NA to NA)	Loracarbef (J01DC08)
14,854,799	68,782,738	NA	NA (NA to NA)	Lymecycline (J01AA04)
14,854,799	68,782,720	146	0 (0 to 0)	Meropenem (J01DH02)

IQVIA Germany				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
14,854,799	68,782,738	NA	NA (NA to NA)	Metacycline (J01AA05)
14,854,799	68,782,736	24	0 (0 to 0)	Mezlocillin (J01CA10)
14,854,799	68,782,738	NA	NA (NA to NA)	Midecamycin (J01FA03)
14,854,379	68,771,042	51,396	74 (74 to 75)	Minocycline (J01AA08)
14,854,799	68,782,738	NA	NA (NA to NA)	Miocamycin (J01FA11)
14,854,772	68,774,137	84,238	122 (121 to 123)	Moxifloxacin (J01MA14)
14,854,799	68,782,738	NA	NA (NA to NA)	Nemonoxacin (J01MB08)
14,854,730	68,779,365	22,262	32 (31 to 32)	Neomycin (A07AA01, J01GB05)
14,854,799	68,782,738	NA	NA (NA to NA)	Netilmicin (J01GB07)
14,854,765	68,777,891	50,757	73 (73 to 74)	Norfloxacin (J01MA06)
14,854,523	68,758,507	173,556	252 (251 to 253)	Ofloxacin (J01MA01)
14,854,799	68,782,738	NA	NA (NA to NA)	Oleandomycin (J01FA05)
14,854,799	68,782,738	NA	NA (NA to NA)	Oxolinic-acid (J01MB05)
14,854,796	68,782,664	685	0 (0 to 1)	Oxytetracycline (J01AA06)
14,854,799	68,782,738	NA	NA (NA to NA)	Panipenem (J01DH55)
14,854,799	68,782,738	NA	NA (NA to NA)	Pazufloxacin (J01MA18)
14,854,799	68,782,738	NA	NA (NA to NA)	Pefloxacin (J01MA03)
14,854,799	68,782,738	NA	NA (NA to NA)	Pheneticillin (J01CE05)
14,854,799	68,782,738	NA	NA (NA to NA)	Pipemidic-acid (J01MB04)
14,854,799	68,782,736	21	0 (0 to 0)	Piperacillin (J01CA12)
14,854,799	68,782,717	108	0 (0 to 0)	Piperacillin_tazobactam (J01CR05, J01CA12)
14,854,799	68,782,738	NA	NA (NA to NA)	Piromidic-acid (J01MB03)
14,854,799	68,782,738	NA	NA (NA to NA)	Pristinamycin (J01FG01)
14,854,799	68,782,738	NA	NA (NA to NA)	Prulifloxacin (J01MA17)
14,854,799	68,782,738	NA	NA (NA to NA)	Ribostamycin (J01GB10)
14,854,799	68,782,665	435	0 (0 to 0)	Rifabutin (J04AB04)
14,854,768	68,781,442	5,066	7 (7 to 7)	Rifampicin (J04AB02)
14,854,799	68,782,738	NA	NA (NA to NA)	Rifamycin (A07AA13, J04AB03)
14,854,790	68,781,401	5,693	8 (8 to 8)	Rifaximin (A07AA11)
14,854,799	68,782,738	NA	NA (NA to NA)	Rokitamycin (J01FA12)
14,854,799	68,782,738	NA	NA (NA to NA)	Rolitetracycline (J01AA09)
14,854,799	68,782,738	NA	NA (NA to NA)	Rosoxacin (J01MB01)
14,854,639	68,756,922	259,039	376 (375 to 378)	Roxithromycin (J01FA06)
14,854,799	68,782,738	NA	NA (NA to NA)	Rufloxacin (J01MA10)
14,854,799	68,782,738	NA	NA (NA to NA)	Sarecycline (J01AA14)
14,854,799	68,782,738	NA	NA (NA to NA)	Sisomicin (J01GB08)
14,854,799	68,782,738	NA	NA (NA to NA)	Sitafloxacin (J01MA21)

IQVIA Germany				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
14,854,799	68,782,738	NA	NA (NA to NA)	Solithromycin (J01FA16)
14,854,799	68,782,738	NA	NA (NA to NA)	Sparfloxacin (J01MA09)
14,854,799	68,782,720	138	0 (0 to 0)	Spiramycin (J01FA02)
14,854,799	68,782,738	NA	NA (NA to NA)	Streptoduocin (J01GA02)
14,854,799	68,782,736	7	0 (0 to 0)	Streptomycin (A07AA04, J01GA01)
14,854,799	68,782,738	NA	NA (NA to NA)	Sulbenicillin (J01CA16)
14,854,799	68,782,738	NA	NA (NA to NA)	Tazobactam (J01CG02)
14,854,799	68,782,738	NA	NA (NA to NA)	Tebipenem (J01DH06)
14,854,799	68,782,737	12	0 (0 to 0)	Teicoplanin (J01XA02)
14,854,798	68,782,619	1,172	1 (1 to 1)	Telithromycin (J01FA15)
14,854,799	68,782,738	NA	NA (NA to NA)	Temafloxacin (J01MA05)
14,854,799	68,782,738	NA	NA (NA to NA)	Temocillin (J01CA17)
14,854,799	68,782,738	NA	NA (NA to NA)	Ticarillin (J01CA13)
14,854,798	68,782,605	695	1 (0 to 1)	Tobramycin (J01GB01)
14,854,799	68,782,738	NA	NA (NA to NA)	Tosufloxacin (J01MA22)
14,854,799	68,782,738	NA	NA (NA to NA)	Troleandomycin (J01FA08)
14,854,799	68,782,738	NA	NA (NA to NA)	Trovafloracin (J01MA13)
14,854,793	68,782,185	4,516	6 (6 to 6)	Vancomycin (A07AA09, J01XA01)

SIDIAP				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
7,310,575	60,128,005	NA	NA (NA to NA)	Arbekacin (J01GB12)
7,310,575	60,128,005	NA	NA (NA to NA)	Aspoxicillin (J01CA19)
7,310,099	59,947,640	1,539,019	2,567 (2,563 to 2,571)	Azithromycin (J01FA10)
7,310,575	60,128,005	NA	NA (NA to NA)	Azlocillin (J01CA09)
7,310,575	60,128,005	NA	NA (NA to NA)	Bekanamycin (J01GB13)
7,310,575	60,128,005	NA	NA (NA to NA)	Biapenem (J01DH05)
7,310,575	60,128,005	NA	NA (NA to NA)	Carbenicillin (J01CA03)
7,310,575	60,128,005	NA	NA (NA to NA)	Carindacillin (J01CA05)
7,310,573	60,126,950	4,830	8 (7 to 8)	Cefaclor (J01DC04)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefamandole (J01DC03)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefbuperazone (J01DC13)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefcapene-pivoxil (J01DD17)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefdinir (J01DD15)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefepime (J01DE01)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefetamet-pivoxil (J01DD10)
7,310,541	60,103,499	207,821	345 (344 to 347)	Cefixime (J01DD08)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefmenoxime (J01DD05)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1 Dissemination level: Public

SIDIAP				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefmetazole (J01DC09)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefminox (J01DC12)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefodizime (J01DD09)
7,310,575	60,127,530	4,643	7 (7 to 7)	Cefonicid (J01DC06)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefoperazone (J01DD12)
7,310,575	60,128,005	NA	NA (NA to NA)	Ceforanide (J01DC11)
7,310,575	60,127,919	800	1 (1 to 1)	Cefotaxime (J01DD01)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefotetan (J01DC05)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefotiam (J01DC07)
7,310,575	60,127,989	148	0 (0 to 0)	Cefoxitin (J01DC01)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefozopran (J01DE03)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefpiramide (J01DD11)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefpirome (J01DE02)
7,310,574	60,127,911	593	0 (0 to 1)	Cefpodoxime-proxetil (J01DD13)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefprozil (J01DC10)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefsulodin (J01DD03)
7,310,575	60,127,924	698	1 (1 to 1)	Ceftazidime (J01DD02)
7,310,575	60,128,005	NA	NA (NA to NA)	Cefteram-pivoxil (J01DD18)
7,310,574	60,127,593	3,189	5 (5 to 5)	Ceftibuten (J01DD14)
7,310,575	60,128,005	NA	NA (NA to NA)	Ceftizoxime (J01DD07)
7,310,573	60,126,288	17,680	29 (28 to 29)	Ceftriaxone (J01DD04)
7,310,540	60,062,372	576,002	959 (956 to 961)	Cefuroxime (J01DC02)
7,310,575	60,128,005	NA	NA (NA to NA)	Chlortetracycline (J01AA03)
7,310,575	60,128,005	NA	NA (NA to NA)	Cinoxacin (J01MB06)
7,310,407	59,979,475	1,258,448	2,098 (2,094 to 2,101)	Ciprofloxacin (J01MA02)
7,310,545	60,071,762	488,454	813 (810 to 815)	Clarithromycin (J01FA09)
7,310,575	60,128,005	NA	NA (NA to NA)	Clofoctol (J01XX03)
7,310,575	60,128,005	NA	NA (NA to NA)	Clomocycline (J01AA11)
7,310,575	60,128,005	NA	NA (NA to NA)	Delafloxacin (J01MA23)
7,310,575	60,128,005	NA	NA (NA to NA)	Demeclocycline (J01AA01)
7,310,575	60,128,005	NA	NA (NA to NA)	Dibekacin (J01GB09)
7,310,575	60,128,005	NA	NA (NA to NA)	Dirithromycin (J01FA13)
7,310,575	60,128,005	NA	NA (NA to NA)	Doripenem (J01DH04)
7,310,575	60,128,005	NA	NA (NA to NA)	Enoxacin (J01MA04)
7,310,575	60,128,005	NA	NA (NA to NA)	Ertapenem (J01DH03)
7,310,572	60,121,157	56,581	94 (93 to 94)	Erythromycin (J01FA01)
7,310,575	60,128,005	NA	NA (NA to NA)	Fidaxomicin (A07AA12)
7,310,575	60,128,005	NA	NA (NA to NA)	Fleroxacin (J01MA08)
7,310,575	60,128,005	NA	NA (NA to NA)	Flomoxef (J01DC14)
7,310,575	60,128,005	NA	NA (NA to NA)	Flumequine (J01MB07)

SIDIAP				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
7,310,575	60,128,005	NA	NA (NA to NA)	Flurithromycin (J01FA14)
7,310,473	59,923,731	1,896,813	3,165 (3,160 to 3,169)	Fosfomycin (J01XX01)
7,310,572	60,126,253	13,937	23 (22 to 23)	Fusidic-acid (J01XC01)
7,310,575	60,128,005	NA	NA (NA to NA)	Garenoxacin (J01MA19)
7,310,575	60,128,005	NA	NA (NA to NA)	Gatifloxacin (J01MA16)
7,310,575	60,128,005	NA	NA (NA to NA)	Gemifloxacin (J01MA15)
7,310,575	60,128,005	NA	NA (NA to NA)	Grepafloxacin (J01MA11)
7,310,575	60,128,005	NA	NA (NA to NA)	Imipenem_cilastatin (J01DH51)
7,310,575	60,128,005	NA	NA (NA to NA)	Isepamicin (J01GB11)
7,310,568	60,124,765	25,746	42 (42 to 43)	Josamycin (J01FA07)
7,310,575	60,128,005	NA	NA (NA to NA)	Kanamycin (A07AA08, J01GB04)
7,310,575	60,128,005	NA	NA (NA to NA)	Lascufloxacin (J01MA25)
7,310,575	60,128,005	NA	NA (NA to NA)	Latamoxef (J01DD06)
7,310,461	60,023,867	891,616	1,485 (1,482 to 1,488)	Levofloxacin (J01MA12)
7,310,575	60,128,005	NA	NA (NA to NA)	Levonadifloxacin (J01MA24)
7,310,574	60,127,740	2,231	3 (3 to 3)	Lincomycin (J01FF02)
7,310,575	60,128,005	NA	NA (NA to NA)	Lomefloxacin (J01MA07)
7,310,575	60,128,005	NA	NA (NA to NA)	Loracarbef (J01DC08)
7,310,575	60,128,005	NA	NA (NA to NA)	Lymecycline (J01AA04)
7,310,575	60,128,005	NA	NA (NA to NA)	Meropenem (J01DH02)
7,310,575	60,128,005	NA	NA (NA to NA)	Metacycline (J01AA05)
7,310,575	60,128,005	NA	NA (NA to NA)	Mezlocillin (J01CA10)
7,310,575	60,128,005	NA	NA (NA to NA)	Midecamycin (J01FA03)
7,310,550	60,116,768	42,366	70 (69 to 71)	Minocycline (J01AA08)
7,310,575	60,127,946	380	0 (0 to 0)	Miocamycin (J01FA11)
7,310,554	60,114,972	113,382	188 (187 to 189)	Moxifloxacin (J01MA14)
7,310,575	60,128,005	NA	NA (NA to NA)	Nemonoxacin (J01MB08)
7,310,565	60,127,633	1,858	3 (2 to 3)	Neomycin (A07AA01, J01GB05)
7,310,575	60,128,005	NA	NA (NA to NA)	Netilmicin (J01GB07)
7,310,364	60,081,141	374,515	623 (621 to 625)	Norfloxacin (J01MA06)
7,310,573	60,127,582	2,505	4 (4 to 4)	Ofloxacin (J01MA01)
7,310,575	60,128,005	NA	NA (NA to NA)	Oleandomycin (J01FA05)
7,310,575	60,128,005	NA	NA (NA to NA)	Oxolinic-acid (J01MB05)
7,310,574	60,121,972	51,425	85 (84 to 86)	Oxytetracycline (J01AA06)
7,310,575	60,128,005	NA	NA (NA to NA)	Panipenem (J01DH55)
7,310,575	60,128,005	NA	NA (NA to NA)	Pazufloxacin (J01MA18)
7,310,575	60,128,005	NA	NA (NA to NA)	Pefloxacin (J01MA03)
7,310,575	60,128,005	NA	NA (NA to NA)	Pheneticillin (J01CE05)
7,310,575	60,128,005	NA	NA (NA to NA)	Pipemidic-acid (J01MB04)
7,310,575	60,128,005	NA	NA (NA to NA)	Piperacillin (J01CA12)

SIDIAP				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
7,310,575	60,128,005	NA	NA (NA to NA)	Piperacillin_tazobactam (J01CR05, J01CA12)
7,310,575	60,128,005	NA	NA (NA to NA)	Piromidic-acid (J01MB03)
7,310,575	60,128,005	NA	NA (NA to NA)	Pristinamycin (J01FG01)
7,310,575	60,128,005	NA	NA (NA to NA)	Prulifloxacin (J01MA17)
7,310,575	60,128,005	NA	NA (NA to NA)	Ribostamycin (J01GB10)
7,310,571	60,127,693	565	0 (0 to 1)	Rifabutin (J04AB04)
7,310,534	60,117,037	28,128	46 (46 to 47)	Rifampicin (J04AB02)
7,310,575	60,128,005	NA	NA (NA to NA)	Rifamycin (A07AA13, J04AB03)
7,310,167	60,069,500	104,457	173 (172 to 174)	Rifaximin (A07AA11)
7,310,575	60,128,005	NA	NA (NA to NA)	Rokitamycin (J01FA12)
7,310,575	60,128,005	NA	NA (NA to NA)	Rolitetracycline (J01AA09)
7,310,575	60,128,005	NA	NA (NA to NA)	Rosoxacin (J01MB01)
7,310,574	60,127,872	1,017	1 (1 to 1)	Roxithromycin (J01FA06)
7,310,575	60,128,005	NA	NA (NA to NA)	Rufloxacin (J01MA10)
7,310,575	60,128,005	NA	NA (NA to NA)	Sarecycline (J01AA14)
7,310,575	60,128,005	NA	NA (NA to NA)	Sisomicin (J01GB08)
7,310,575	60,128,005	NA	NA (NA to NA)	Sitafloxacin (J01MA21)
7,310,575	60,128,005	NA	NA (NA to NA)	Solithromycin (J01FA16)
7,310,575	60,128,005	NA	NA (NA to NA)	Sparfloxacin (J01MA09)
7,310,570	60,120,779	58,797	97 (97 to 98)	Spiramycin (J01FA02)
7,310,575	60,128,005	NA	NA (NA to NA)	Streptoduocin (J01GA02)
7,310,575	60,127,991	42	0 (0 to 0)	Streptomycin (A07AA04, J01GA01)
7,310,575	60,128,005	NA	NA (NA to NA)	Sulbenicillin (J01CA16)
7,310,575	60,128,005	NA	NA (NA to NA)	Tazobactam (J01CG02)
7,310,575	60,128,005	NA	NA (NA to NA)	Tebipenem (J01DH06)
7,310,575	60,128,005	NA	NA (NA to NA)	Teicoplanin (J01XA02)
7,310,572	60,127,902	306	0 (0 to 0)	Telithromycin (J01FA15)
7,310,575	60,128,005	NA	NA (NA to NA)	Temafloxacin (J01MA05)
7,310,575	60,128,005	NA	NA (NA to NA)	Temocillin (J01CA17)
7,310,575	60,128,005	NA	NA (NA to NA)	Ticarcillin (J01CA13)
7,310,569	60,127,133	5,233	8 (8 to 8)	Tobramycin (J01GB01)
7,310,575	60,128,005	NA	NA (NA to NA)	Tosufloxacin (J01MA22)
7,310,575	60,128,005	NA	NA (NA to NA)	Troleandomycin (J01FA08)
7,310,575	60,128,005	NA	NA (NA to NA)	Trovafloxacin (J01MA13)
7,310,574	60,127,867	896	1 (1 to 1)	Vancomycin (A07AA09, J01XA01)

IMASIS				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
339,946	1,876,517	NA	NA (NA to NA)	Arbekacin (J01GB12)
339,946	1,876,517	NA	NA (NA to NA)	Aspoxicillin (J01CA19)
339,937	1,875,224	15,598	831 (818 to 844)	Azithromycin (J01FA10)
339,946	1,876,517	NA	NA (NA to NA)	Azlocillin (J01CA09)
339,946	1,876,517	NA	NA (NA to NA)	Bekanamycin (J01GB13)
339,946	1,876,517	NA	NA (NA to NA)	Biapenem (J01DH05)
339,946	1,876,517	NA	NA (NA to NA)	Carbencillin (J01CA03)
339,946	1,876,517	NA	NA (NA to NA)	Carindacillin (J01CA05)
339,946	1,876,516	5	0 (0 to 0)	Cefaclor (J01DC04)
339,946	1,876,517	NA	NA (NA to NA)	Cefamandole (J01DC03)
339,946	1,876,517	NA	NA (NA to NA)	Cefbuperazone (J01DC13)
339,946	1,876,517	NA	NA (NA to NA)	Cefcapene-pivoxil (J01DD17)
339,946	1,876,517	NA	NA (NA to NA)	Cefdinir (J01DD15)
339,946	1,876,466	582	31 (28 to 33)	Cefepime (J01DE01)
339,944	1,876,197	3,650	194 (188 to 200)	Cefixime (J01DD08)
339,946	1,876,517	NA	NA (NA to NA)	Cefmenoxime (J01DD05)
339,946	1,876,517	NA	NA (NA to NA)	Cefmetazole (J01DC09)
339,946	1,876,517	NA	NA (NA to NA)	Cefminox (J01DC12)
339,946	1,876,517	NA	NA (NA to NA)	Cefodizime (J01DD09)
339,946	1,876,472	546	29 (26 to 31)	Cefonicid (J01DC06)
339,946	1,876,517	NA	NA (NA to NA)	Cefoperazone (J01DD12)
339,946	1,876,517	NA	NA (NA to NA)	Ceforanide (J01DC11)
339,944	1,875,928	6,602	351 (343 to 360)	Cefotaxime (J01DD01)
339,946	1,876,517	NA	NA (NA to NA)	Cefotetan (J01DC05)
339,946	1,876,517	NA	NA (NA to NA)	Cefotiam (J01DC07)
339,946	1,876,499	212	11 (9 to 12)	Cefoxitin (J01DC01)
339,946	1,876,517	NA	NA (NA to NA)	Cefozopran (J01DE03)
339,946	1,876,517	NA	NA (NA to NA)	Cefpiramide (J01DD11)
339,946	1,876,517	NA	NA (NA to NA)	Cefpirome (J01DE02)
339,946	1,876,517	NA	NA (NA to NA)	Cefpodoxime-proxetil (J01DD13)
339,946	1,876,517	NA	NA (NA to NA)	Cefprozil (J01DC10)
339,946	1,876,517	NA	NA (NA to NA)	Cefsulodin (J01DD03)
339,939	1,876,217	3,031	161 (155 to 167)	Ceftazidime (J01DD02)
339,946	1,876,517	NA	NA (NA to NA)	Cefteram-pivoxil (J01DD18)
339,946	1,876,515	14	0 (0 to 1)	Ceftibuten (J01DD14)
339,946	1,876,517	NA	NA (NA to NA)	Ceftizoxime (J01DD07)
339,930	1,875,032	18,379	980 (966 to 994)	Ceftriaxone (J01DD04)
339,944	1,876,296	2,702	144 (138 to 149)	Cefuroxime (J01DC02)
339,946	1,876,517	NA	NA (NA to NA)	Chlortetracycline (J01AA03)
339,946	1,876,517	NA	NA (NA to NA)	Cinoxacin (J01MB06)

IMASIS				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
339,935	1,874,378	22,747	1,213 (1,197 to 1,229)	Ciprofloxacin (J01MA02)
339,946	1,876,371	1,705	90 (86 to 95)	Clarithromycin (J01FA09)
339,946	1,876,517	NA	NA (NA to NA)	Clofoctol (J01XX03)
339,946	1,876,517	NA	NA (NA to NA)	Clomocycline (J01AA11)
339,946	1,876,517	NA	NA (NA to NA)	Delafloxacin (J01MA23)
339,946	1,876,517	NA	NA (NA to NA)	Demeclocycline (J01AA01)
339,946	1,876,517	NA	NA (NA to NA)	Dibekacin (J01GB09)
339,946	1,876,517	NA	NA (NA to NA)	Dirithromycin (J01FA13)
339,946	1,876,516	12	0 (0 to 1)	Doripenem (J01DH04)
339,946	1,876,517	NA	NA (NA to NA)	Enoxacin (J01MA04)
339,943	1,876,224	2,994	159 (153 to 165)	Ertapenem (J01DH03)
339,945	1,876,373	1,725	91 (87 to 96)	Erythromycin (J01FA01)
339,946	1,876,517	NA	NA (NA to NA)	Fidaxomicin (A07AA12)
339,946	1,876,517	NA	NA (NA to NA)	Fleroxacin (J01MA08)
339,946	1,876,517	NA	NA (NA to NA)	Flomoxef (J01DC14)
339,946	1,876,517	NA	NA (NA to NA)	Flumequine (J01MB07)
339,946	1,876,502	155	8 (7 to 9)	Flurithromycin (J01FA14)
339,943	1,875,223	15,575	830 (817 to 843)	Fosfomycin (J01XX01)
339,946	1,876,514	29	1 (1 to 2)	Fusidic-acid (J01XC01)
339,946	1,876,517	NA	NA (NA to NA)	Garenoxacin (J01MA19)
339,946	1,876,517	NA	NA (NA to NA)	Gatifloxacin (J01MA16)
339,946	1,876,517	NA	NA (NA to NA)	Gemifloxacin (J01MA15)
339,946	1,876,517	NA	NA (NA to NA)	Grepafloxacin (J01MA11)
339,946	1,876,517	NA	NA (NA to NA)	Imipenem_cilastatin (J01DH51)
339,946	1,876,517	NA	NA (NA to NA)	Isepamicin (J01GB11)
339,946	1,876,513	39	2 (1 to 2)	Josamycin (J01FA07)
339,946	1,876,517	NA	NA (NA to NA)	Kanamycin (A07AA08, J01GB04)
339,946	1,876,517	NA	NA (NA to NA)	Lascufloxacin (J01MA25)
339,946	1,876,517	NA	NA (NA to NA)	Latamoxef (J01DD06)
339,925	1,874,421	22,843	1,218 (1,202 to 1,234)	Levofloxacin (J01MA12)
339,946	1,876,517	NA	NA (NA to NA)	Levonadifloxacin (J01MA24)
339,946	1,876,516	6	0 (0 to 0)	Lincomycin (J01FF02)
339,946	1,876,517	NA	NA (NA to NA)	Lomefloxacin (J01MA07)
339,946	1,876,517	NA	NA (NA to NA)	Loracarbef (J01DC08)
339,946	1,876,517	NA	NA (NA to NA)	Lymecycline (J01AA04)
339,938	1,876,019	5,206	277 (270 to 285)	Meropenem (J01DH02)
339,946	1,876,517	NA	NA (NA to NA)	Metacycline (J01AA05)
339,946	1,876,517	NA	NA (NA to NA)	Mezlocillin (J01CA10)
339,946	1,876,517	NA	NA (NA to NA)	Midecamycin (J01FA03)
339,946	1,876,431	923	49 (46 to 52)	Minocycline (J01AA08)

IMASIS				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
339,946	1,876,517	NA	NA (NA to NA)	Miocamycin (J01FA11)
339,946	1,876,451	778	41 (38 to 44)	Moxifloxacin (J01MA14)
339,946	1,876,517	NA	NA (NA to NA)	Nemonoxacin (J01MB08)
339,946	1,876,511	63	3 (2 to 4)	Neomycin (A07AA01, J01GB05)
339,946	1,876,517	NA	NA (NA to NA)	Netilmicin (J01GB07)
339,944	1,876,416	858	45 (42 to 48)	Norfloxacin (J01MA06)
339,946	1,876,517	NA	NA (NA to NA)	Ofloxacin (J01MA01)
339,946	1,876,517	NA	NA (NA to NA)	Oleandomycin (J01FA05)
339,946	1,876,517	NA	NA (NA to NA)	Oxolinic-acid (J01MB05)
339,946	1,876,501	183	9 (8 to 11)	Oxytetracycline (J01AA06)
339,946	1,876,517	NA	NA (NA to NA)	Panipenem (J01DH55)
339,946	1,876,517	NA	NA (NA to NA)	Pazufloxacin (J01MA18)
339,946	1,876,517	NA	NA (NA to NA)	Pefloxacin (J01MA03)
339,946	1,876,517	NA	NA (NA to NA)	Pheneticillin (J01CE05)
339,946	1,876,517	NA	NA (NA to NA)	Pipemidic-acid (J01MB04)
339,946	1,876,517	NA	NA (NA to NA)	Piperacillin (J01CA12)
339,946	1,876,517	12,701	677 (665 to 689)	Piperacillin_tazobactam (J01CR05, J01CA12)
339,946	1,876,517	NA	NA (NA to NA)	Piromidic-acid (J01MB03)
339,946	1,876,517	NA	NA (NA to NA)	Pristinamycin (J01FG01)
339,946	1,876,517	NA	NA (NA to NA)	Prulifloxacin (J01MA17)
339,946	1,876,517	NA	NA (NA to NA)	Ribostamycin (J01GB10)
339,946	1,876,508	72	3 (3 to 4)	Rifabutin (J04AB04)
339,944	1,876,338	1,511	80 (76 to 84)	Rifampicin (J04AB02)
339,946	1,876,517	NA	NA (NA to NA)	Rifamycin (A07AA13, J04AB03)
339,946	1,876,331	1,771	94 (90 to 98)	Rifaximin (A07AA11)
339,946	1,876,517	NA	NA (NA to NA)	Rokitamycin (J01FA12)
339,946	1,876,517	NA	NA (NA to NA)	Rolitetracycline (J01AA09)
339,946	1,876,517	NA	NA (NA to NA)	Rosoxacin (J01MB01)
339,946	1,876,516	NA	NA (NA to NA)	Roxithromycin (J01FA06)
339,946	1,876,517	NA	NA (NA to NA)	Rufloxacin (J01MA10)
339,946	1,876,517	NA	NA (NA to NA)	Sarecycline (J01AA14)
339,946	1,876,517	NA	NA (NA to NA)	Sisomicin (J01GB08)
339,946	1,876,517	NA	NA (NA to NA)	Sitafloxacin (J01MA21)
339,946	1,876,517	NA	NA (NA to NA)	Solithromycin (J01FA16)
339,946	1,876,517	NA	NA (NA to NA)	Sparfloxacin (J01MA09)
339,946	1,876,513	32	1 (1 to 2)	Spiramycin (J01FA02)
339,946	1,876,517	NA	NA (NA to NA)	Streptoduocin (J01GA02)
339,946	1,876,514	17	0 (0 to 1)	Streptomycin (A07AA04, J01GA01)
339,946	1,876,517	NA	NA (NA to NA)	Sulbenicillin (J01CA16)

IMASIS				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
339,946	1,876,517	NA	NA (NA to NA)	Tazobactam (J01CG02)
339,946	1,876,517	NA	NA (NA to NA)	Tebipenem (J01DH06)
339,946	1,876,517	NA	NA (NA to NA)	Teicoplanin (J01XA02)
339,946	1,876,516	NA	NA (NA to NA)	Telithromycin (J01FA15)
339,946	1,876,517	NA	NA (NA to NA)	Temafloxacin (J01MA05)
339,946	1,876,517	NA	NA (NA to NA)	Temocillin (J01CA17)
339,946	1,876,517	NA	NA (NA to NA)	Ticarcillin (J01CA13)
339,946	1,876,489	264	14 (12 to 15)	Tobramycin (J01GB01)
339,946	1,876,517	NA	NA (NA to NA)	Tosufloxacin (J01MA22)
339,946	1,876,517	NA	NA (NA to NA)	Troleandomycin (J01FA08)
339,946	1,876,517	NA	NA (NA to NA)	Trovafloxacin (J01MA13)
339,945	1,876,216	3,190	170 (164 to 176)	Vancomycin (A07AA09, J01XA01)

CHUBX				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
925,321	4,556,187	NA	NA (NA to NA)	Arbekacin (J01GB12)
925,321	4,556,187	NA	NA (NA to NA)	Aspoxicillin (J01CA19)
925,318	4,555,873	3,448	75 (73 to 78)	Azithromycin (J01FA10)
925,321	4,556,187	NA	NA (NA to NA)	Azlocillin (J01CA09)
925,321	4,556,187	NA	NA (NA to NA)	Bekanamycin (J01GB13)
925,321	4,556,187	NA	NA (NA to NA)	Biapenem (J01DH05)
925,321	4,556,187	NA	NA (NA to NA)	Carbenicillin (J01CA03)
925,321	4,556,187	NA	NA (NA to NA)	Carindacillin (J01CA05)
925,321	4,556,176	107	2 (1 to 2)	Cefaclor (J01DC04)
925,321	4,556,187	NA	NA (NA to NA)	Cefamandole (J01DC03)
925,321	4,556,187	NA	NA (NA to NA)	Cefbuperazone (J01DC13)
925,321	4,556,187	NA	NA (NA to NA)	Cefcapene-pivoxil (J01DD17)
925,321	4,556,187	NA	NA (NA to NA)	Cefdinir (J01DD15)
925,319	4,556,006	2,026	44 (42 to 46)	Cefepime (J01DE01)
925,321	4,556,187	NA	NA (NA to NA)	Cefetamet-pivoxil (J01DD10)
925,320	4,556,038	1,713	37 (35 to 39)	Cefixime (J01DD08)
925,321	4,556,187	NA	NA (NA to NA)	Cefmenoxime (J01DD05)
925,321	4,556,187	NA	NA (NA to NA)	Cefmetazole (J01DC09)
925,321	4,556,187	NA	NA (NA to NA)	Cefminox (J01DC12)
925,321	4,556,187	NA	NA (NA to NA)	Cefodizime (J01DD09)
925,321	4,556,187	NA	NA (NA to NA)	Cefonicid (J01DC06)
925,321	4,556,187	NA	NA (NA to NA)	Cefoperazone (J01DD12)
925,321	4,556,187	NA	NA (NA to NA)	Ceforanide (J01DC11)

CHUBX				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
925,318	4,556,061	1,599	35 (33 to 36)	Cefotaxime (J01DD01)
925,321	4,556,187	NA	NA (NA to NA)	Cefotetan (J01DC05)
925,321	4,556,187	NA	NA (NA to NA)	Cefotiam (J01DC07)
925,321	4,556,092	1,147	25 (23 to 26)	Cefoxitin (J01DC01)
925,321	4,556,187	NA	NA (NA to NA)	Cefozopran (J01DE03)
925,321	4,556,187	NA	NA (NA to NA)	Cefpiramide (J01DD11)
925,321	4,556,187	NA	NA (NA to NA)	Cefpirome (J01DE02)
925,321	4,556,168	216	4 (4 to 5)	Cefpodoxime-proxetil (J01DD13)
925,321	4,556,187	NA	NA (NA to NA)	Cefprozil (J01DC10)
925,321	4,556,187	NA	NA (NA to NA)	Cefsulodin (J01DD03)
925,317	4,555,921	2,910	63 (61 to 66)	Ceftazidime (J01DD02)
925,321	4,556,187	NA	NA (NA to NA)	Cefteram-pivoxil (J01DD18)
925,321	4,556,187	NA	NA (NA to NA)	Ceftibuten (J01DD14)
925,321	4,556,187	NA	NA (NA to NA)	Ceftizoxime (J01DD07)
925,250	4,552,724	43,764	961 (952 to 970)	Ceftriaxone (J01DD04)
925,316	4,556,050	1,628	35 (34 to 37)	Cefuroxime (J01DC02)
925,321	4,556,187	NA	NA (NA to NA)	Chlortetracycline (J01AA03)
925,321	4,556,187	NA	NA (NA to NA)	Cinoxacin (J01MB06)
925,309	4,555,386	8,733	191 (187 to 195)	Ciprofloxacin (J01MA02)
925,320	4,556,109	821	18 (16 to 19)	Clarithromycin (J01FA09)
925,321	4,556,187	NA	NA (NA to NA)	Clofoctol (J01XX03)
925,321	4,556,187	NA	NA (NA to NA)	Clomocycline (J01AA11)
925,321	4,556,187	NA	NA (NA to NA)	Delafloxacin (J01MA23)
925,321	4,556,186	15	0 (0 to 0)	Demeclocycline (J01AA01)
925,321	4,556,187	NA	NA (NA to NA)	Dibekacin (J01GB09)
925,321	4,556,187	NA	NA (NA to NA)	Dirithromycin (J01FA13)
925,321	4,556,176	124	2 (2 to 3)	Doripenem (J01DH04)
925,321	4,556,187	NA	NA (NA to NA)	Enoxacin (J01MA04)
925,321	4,556,110	916	20 (18 to 21)	Ertapenem (J01DH03)
925,316	4,555,906	2,928	64 (61 to 66)	Erythromycin (J01FA01)
925,321	4,556,160	290	6 (5 to 7)	Fidaxomicin (A07AA12)
925,321	4,556,187	NA	NA (NA to NA)	Fleroxacin (J01MA08)
925,321	4,556,187	NA	NA (NA to NA)	Flomoxef (J01DC14)
925,321	4,556,187	NA	NA (NA to NA)	Flumequine (J01MB07)
925,320	4,556,109	821	18 (16 to 19)	Flurithromycin (J01FA14)
925,320	4,556,096	1,156	25 (23 to 26)	Fosfomycin (J01XX01)
925,321	4,556,187	NA	NA (NA to NA)	Fusidic-acid (J01XC01)
925,321	4,556,187	NA	NA (NA to NA)	Garenoxacin (J01MA19)
925,321	4,556,187	NA	NA (NA to NA)	Gatifloxacin (J01MA16)
925,321	4,556,187	NA	NA (NA to NA)	Gemifloxacin (J01MA15)

CHUBX				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
925,321	4,556,187	NA	NA (NA to NA)	Grepafloxacin (J01MA11)
925,312	4,555,938	2,670	58 (56 to 60)	Imipenem_cilastatin (J01DH51)
925,321	4,556,187	NA	NA (NA to NA)	Isepamicin (J01GB11)
925,321	4,556,185	23	0 (0 to 0)	Josamycin (J01FA07)
925,321	4,556,187	NA	NA (NA to NA)	Kanamycin (A07AA08, J01GB04)
925,321	4,556,187	NA	NA (NA to NA)	Lascufloxacin (J01MA25)
925,321	4,556,187	NA	NA (NA to NA)	Latamoxef (J01DD06)
925,318	4,555,621	5,985	131 (128 to 134)	Levofloxacin (J01MA12)
925,321	4,556,187	NA	NA (NA to NA)	Levonadifloxacin (J01MA24)
925,321	4,556,187	NA	NA (NA to NA)	Lincomycin (J01FF02)
925,321	4,556,186	6	0 (0 to 0)	Lomefloxacin (J01MA07)
925,321	4,556,187	NA	NA (NA to NA)	Loracarbef (J01DC08)
925,321	4,556,181	54	1 (0 to 1)	Lymecycline (J01AA04)
925,320	4,555,987	2,138	46 (44 to 48)	Meropenem (J01DH02)
925,321	4,556,186	9	0 (0 to 0)	Metacycline (J01AA05)
925,321	4,556,187	NA	NA (NA to NA)	Mezlocillin (J01CA10)
925,321	4,556,187	NA	NA (NA to NA)	Midecamycin (J01FA03)
925,321	4,556,183	40	0 (0 to 1)	Minocycline (J01AA08)
925,321	4,556,187	NA	NA (NA to NA)	Miocamycin (J01FA11)
925,321	4,556,155	292	6 (5 to 7)	Moxifloxacin (J01MA14)
925,321	4,556,187	NA	NA (NA to NA)	Nemonoxacin (J01MB08)
925,321	4,556,187	NA	NA (NA to NA)	Neomycin (A07AA01, J01GB05)
925,321	4,556,187	NA	NA (NA to NA)	Netilmicin (J01GB07)
925,320	4,556,103	889	19 (18 to 20)	Norfloxacin (J01MA06)
925,311	4,555,341	9,299	204 (200 to 208)	Ofloxacin (J01MA01)
925,321	4,556,187	NA	NA (NA to NA)	Oleandomycin (J01FA05)
925,321	4,556,187	NA	NA (NA to NA)	Oxolinic-acid (J01MB05)
925,321	4,556,187	NA	NA (NA to NA)	Oxytetracycline (J01AA06)
925,321	4,556,187	NA	NA (NA to NA)	Panipenem (J01DH55)
925,321	4,556,187	NA	NA (NA to NA)	Pazufloxacin (J01MA18)
925,321	4,556,187	NA	NA (NA to NA)	Pefloxacin (J01MA03)
925,321	4,556,187	NA	NA (NA to NA)	Pheneticillin (J01CE05)
925,321	4,556,187	NA	NA (NA to NA)	Pipemidic-acid (J01MB04)
925,279	4,554,175	22,424	492 (485 to 498)	Piperacillin (J01CA12)
925,279	4,554,169	22,473	493 (487 to 499)	Piperacillin_tazobactam (J01CR05, J01CA12)
925,321	4,556,187	NA	NA (NA to NA)	Piromidic-acid (J01MB03)
925,313	4,555,959	2,512	55 (53 to 57)	Pristinamycin (J01FG01)
925,321	4,556,187	NA	NA (NA to NA)	Prulifloxacin (J01MA17)
925,321	4,556,187	NA	NA (NA to NA)	Ribostamycin (J01GB10)
925,321	4,556,170	123	2 (2 to 3)	Rifabutin (J04AB04)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1 Dissemination level: Public


CHUBX				
n_persons	person_years	n_prescriptions	incidence_100,000_pys (95% CI)	Antibiotic (ATC code)
925,312	4,555,776	3,642	79 (77 to 82)	Rifampicin (J04AB02)
925,321	4,556,187	NA	NA (NA to NA)	Rifamycin (A07AA13, J04AB03)
925,319	4,556,087	917	20 (18 to 21)	Rifaximin (A07AA11)
925,321	4,556,187	NA	NA (NA to NA)	Rokitamycin (J01FA12)
925,321	4,556,187	NA	NA (NA to NA)	Rolitetracycline (J01AA09)
925,321	4,556,187	NA	NA (NA to NA)	Rosoxacin (J01MB01)
925,321	4,556,182	62	1 (1 to 1)	Roxithromycin (J01FA06)
925,321	4,556,187	NA	NA (NA to NA)	Rufloxacin (J01MA10)
925,321	4,556,187	NA	NA (NA to NA)	Sarecycline (J01AA14)
925,321	4,556,187	NA	NA (NA to NA)	Sisomicin (J01GB08)
925,321	4,556,187	NA	NA (NA to NA)	Sitafloxacin (J01MA21)
925,321	4,556,187	NA	NA (NA to NA)	Solithromycin (J01FA16)
925,321	4,556,187	NA	NA (NA to NA)	Sparfloxacin (J01MA09)
925,313	4,555,746	5,717	125 (122 to 128)	Spiramycin (J01FA02)
925,321	4,556,176	58	1 (0 to 1)	Streptoduocin (J01GA02)
925,321	4,556,187	NA	NA (NA to NA)	Streptomycin (A07AA04, J01GA01)
925,321	4,556,187	NA	NA (NA to NA)	Sulbenicillin (J01CA16)
925,279	4,554,181	22,380	491 (484 to 497)	Tazobactam (J01CG02)
925,321	4,556,187	NA	NA (NA to NA)	Tebipenem (J01DH06)
925,321	4,556,170	195	4 (3 to 4)	Teicoplanin (J01XA02)
925,321	4,556,187	NA	NA (NA to NA)	Telithromycin (J01FA15)
925,321	4,556,187	NA	NA (NA to NA)	Temafloxacin (J01MA05)
925,320	4,556,174	145	3 (2 to 3)	Temocillin (J01CA17)
925,320	4,556,135	583	12 (11 to 13)	Ticarcillin (J01CA13)
925,319	4,555,818	4,073	89 (86 to 92)	Tobramycin (J01GB01)
925,321	4,556,187	NA	NA (NA to NA)	Tosufloxacin (J01MA22)
925,321	4,556,187	NA	NA (NA to NA)	Troleandomycin (J01FA08)
925,321	4,556,187	NA	NA (NA to NA)	Trovafloxacin (J01MA13)
925,314	4,555,633	6,069	133 (129 to 136)	Vancomycin (A07AA09, J01XA01)

NA= number of prescriptions <=5

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
		Dissemination level: Public

TABLE 2– ANTIBIOTIC SUBCLASS AND INDIVIDUAL ANTIBIOTICS FROM THE WHO WATCH LIST

Antibiotic Class	Antibiotic Name
Aminoglycosides	Arbekacin
	Bekanamycin
	Dibekacin
	Isepamicin
	Kanamycin_IV
	Kanamycin_oral
	Micronomicin
	Neomycin
	Netilmicin
	Ribostamycin
	Sisomicin
	Streptoduocin
	Streptomycin
	Tobramycin
Beta-lactam/beta-lactamase-inhibitor_anti-pseudomonal	Piperacilline+tazobactam
Carbapenem	Biapenem
	Doripenem
	Ertapenem
	Imipenem
	Meropenem
	Panipenem
	Tebipenem
Fluoroquinolones	Ciprofloxacin
	Delafloxacin
	Enoxacin
	Fleroxacin
	Garenoxacin
	Gatifloxacin
	Gemifloxacin
	Grepafloxacin
	Lascufloxacin
	Levofloxacin
	Levonadifloxacin
	Lomefloxacin
	Moxifloxacin
	Norfloxacin
	Ofloxacin
Pazufloxacin	

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
		Dissemination level: Public

Antibiotic Class	Antibiotic Name
	Pefloxacin
	Prulifloxacin
	Rufloxacin
	Sitafloracin
	Sparfloxacin
	Temafloracin
	Tosufloxacin
	Trovafloracin
Fourth-generation Cephalosporins	Cefepime
	Cefoselis
	Cefozopran
	Cefpirome
Glycopeptides	Teicoplanin
	Vancomycin_IV
	Vancomycin_oral
Lincosamides	Lincomycin
Macrolides	Azithromycin
	Clarithromycin
	Dirithromycin
	Erythromycin
	Fidaxomicin
	Flurithromycin
	Josamycin
	Midecamycin
	Miocamycin
	Oleandomycin
	Rokitamycin
	Roxithromycin
	Solithromycin
	Spiramycin
	Telithromycin
Troleandomycin	
Penicillins	Aspoxicillin
	Azlocillin
	Carbenicillin
	Carindacillin
	Mezlocillin
	Pheneticillin
	Piperacillin
	Sulbenicillin
	Temocillin
Ticarcillin	

Antibiotic Class	Antibiotic Name
Phenol derivatives	Clofoctol
Phosphonics	Fosfomycin_oral
Quinolones	Cinoxacin
	Flumequine
	Nemonoxacin
	Oxolinic-acid
	Pipemidic-acid
	Piromidic-acid
	Rosoxacin
Rifamycins	Rifabutin
	Rifampicin
	Rifamycin_IV
	Rifamycin_oral
	Rifaximin
Second-generation Cephalosporins	Cefaclor
	Cefamandole
	Cefbuperazone
	Cefmetazole
	Cefminox
	Cefonicid
	Ceforanide
	Cefotetan
	Cefotiam
	Cefoxitin
	Cefprozil
	Cefuroxime
	Flomoxef
	Loracarbef
Steroid antibacterials	Fusidic-acid
Streptogramins	Pristinamycin
Tetracyclines	Chlortetracycline
	Clomocycline
	Demeclocycline
	Lymecycline
	Metacycline
	Minocycline_oral
	Oxytetracycline
	Penimepicycline
	Rolitetracycline
	Sarecycline
Third-generation Cephalosporins	Cefcapene-pivoxil
	Cefdinir

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
		Dissemination level: Public

Antibiotic Class	Antibiotic Name
	Cefditoren-pivoxil
	Cefetamet-pivoxil
	Cefixime
	Cefmenoxime
	Cefodizime
	Cefoperazone
	Cefotaxime
	Cefpiramide
	Cefpodoxime-proxetil
	Cefsulodin
	Ceftazidime
	Cefteram-pivoxil
	Ceftibuten
	Ceftizoxime
	Ceftriaxone
Latamoxef	

	Study Report for C1-003 - Appendix				
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier				Version: v3.1
	Dissemination level: Public				

TABLE 3– DURATION OF ANTIBIOTIC DRUG USE OF TOP 5 OF MOST PRESCRIBED ANTIBIOTICS PER DATABASE

Database name	CPRD GOLD	SIDIAP	IPCI	IQVIA Germany	IMASIS	CHUBX
Antibiotic	Azithromycin (J01FA10)					
Observations	130553	1539019	187076	674777	15598	3448
Subjects	69837	1039468	132325	447207	12210	2224
Duration (min-max)	[1-2420]	[1-4152]	[1-2978]	[1-1500]	[1-150]	[1-944]
Duration (median, p25-p75)	3 [1 - 3]	4 [4 - 4]	3 [3 - 3]	3 [3 - 3]	1 [1 - 1]	3 [1 - 3]
Duration (mean, sd)	21.3 (67.3)	11.7 (87.8)	10.7 (41.6)	4.3 (23.7)	2.1 (3.8)	4.4 (17.2)
Antibiotic	Cefaclor (J01DC04)					
Observations	15857	4830	856	369117	5	107
Subjects	11324	4023	670	242299	5	101
Duration (min-max)	[2-387]	[1-2366]	[1-481]	[1-814]	[1-1]	[1-34]
Duration (median, p25-p75)	7 [5 - 7]	9 [8 - 9]	7 [6 - 7]	5 [1 - 7]	1 [1 - 1]	4 [2 - 4]
Duration (mean, sd)	7.7 (6.9)	38.1 (115.3)	10.9 (25.5)	5.4 (8.3)	1 (0)	6.1 (6.7)
Antibiotic	Ceftriaxone (J01DD04)					
Observations	992	17680	3852	2859	18379	44490
Subjects	890	15454	3361	2468	14931	34702
Duration (min-max)	[1-136]	[1-873]	[1-801]	[1-507]	[1-72]	[1-114]
Duration (median, p25-p75)	7 [4 - 7]	5 [2 - 5]	30 [1 - 30]	7 [2 - 10]	2 [1 - 2]	4 [2 - 4]
Duration (mean, sd)	7.3 (7.2)	9.4 (22.6)	38.8 (52.6)	7.9 (16.7)	3.9 (4.1)	4.8 (4.3)
Antibiotic	Cefuroxime (J01DC02)					
Observations	4640	576002	1748	929894	2702	1647
Subjects	3359	416085	1299	635241	2297	1571
Duration (min-max)	[2-570]	[1-3596]	[1-538]	[1-976]	[1-17]	[1-50]
Duration (median, p25-p75)	7 [7 - 7]	8 [6 - 8]	7 [7 - 7]	6 [6 - 7]	1 [1 - 1]	2 [1 - 2]
Duration (mean, sd)	8.9 (11)	11.4 (34.3)	13.5 (29.6)	7.3 (5.5)	1 (0.5)	2.9 (3.2)
Antibiotic	Ciprofloxacin (J01MA02)					
Observations	369519	1258448	145789	677383	22747	8769
Subjects	239456	802448	97544	454290	16539	7775
Duration (min-max)	[1-1564]	[1-4081]	[1-1586]	[1-757]	[1-115]	[1-352]
Duration (median, p25-p75)	5 [5 - 5]	8 [8 - 8]	7 [7 - 7]	5 [5 - 10]	2 [1 - 2]	4 [2 - 4]
Duration (mean, sd)	7.2 (10.5)	12.5 (39.2)	9.8 (12.8)	7.2 (5.6)	4 (5.5)	6.3 (7.3)

Database name	CPRD GOLD	SIDIAP	IPCI	IQVIA Germany	IMASIS	CHUBX
Antibiotic	Clarithromycin (J01FA09)					
Observations	1288110	488454	83370	329386	1705	821
Subjects	760218	398457	66156	244459	1531	723
Duration (min-max)	[1-1737]	[1-3727]	[1-1089]	[1-700]	[1-26]	[1-90]
Duration (median, p25-p75)	7 [7 - 7]	8 [8 - 8]	7 [7 - 7]	7 [5 - 7]	1 [1 - 1]	5 [3 - 5]
Duration (mean, sd)	7.6 (6.5)	11.8 (31.3)	10.9 (17.6)	6.8 (5.1)	1.4 (1.9)	6.5 (7.7)
Antibiotic	Erythromycin (J01FA01)					
Observations	747601	56581	10660	136769	1725	2943
Subjects	457610	46092	8899	98945	1605	2453
Duration (min-max)	[1-2055]	[1-3495]	[1-1787]	[1-500]	[1-51]	[1-255]
Duration (median, p25-p75)	7 [5 - 7]	9 [8 - 9]	7 [7 - 7]	30 [8 - 30]	1 [1 - 1]	4 [2 - 4]
Duration (mean, sd)	8.7 (14.1)	12.8 (37.4)	15.4 (33.7)	21.7 (12.6)	3.6 (5)	6.3 (9.4)
Antibiotic	Fosfomycin (J01XX01)					
Observations	11222	1896813	116533	404127	15575	1157
Subjects	7720	946159	59801	279874	11736	1111
Duration (min-max)	[1-122]	[1-3923]	[1-1910]	[1-3000]	[1-66]	[1-59]
Duration (median, p25-p75)	1 [1 - 1]	3 [3 - 3]	1 [1 - 1]	1 [1 - 1]	1 [1 - 1]	1 [1 - 1]
Duration (mean, sd)	1.5 (3)	9.1 (64.9)	4.1 (19.7)	1.1 (6.6)	1.4 (1.6)	3.1 (5.4)
Antibiotic	Levofloxacin (J01MA12)					
Observations	10593	891616	7660	224573	22843	6008
Subjects	7314	531224	6485	159060	14648	5391
Duration (min-max)	[3-416]	[1-3527]	[1-533]	[1-938]	[1-126]	[1-109]
Duration (median, p25-p75)	10 [7 - 10]	8 [8 - 8]	14 [7 - 14]	7 [5 - 10]	1 [1 - 1]	4 [1 - 4]
Duration (mean, sd)	10.3 (9.4)	12.2 (41.2)	14.7 (19.4)	7.7 (7.3)	3.8 (4.8)	6.4 (8)
Antibiotic	Lymecycline (J01AA04)					
Observations	313052					54
Subjects	151092					44
Duration (min-max)	[3-2507]					[1-68]
Duration (median, p25-p75)	56 [28 - 56]					4 [2 - 4]
Duration (mean, sd)	59.9 (53.2)					7.6 (10.8)
Antibiotic	Ofloxacin (J01MA01)					
Observations	26405	2505	5937	173681		9316
Subjects	21670	2254	4765	130693		8501

Database name	CPRD GOLD	SIDIAP	IPCI	IQVIA Germany	IMASIS	CHUBX
Duration (min-max)	[3-778]	[1-1840]	[1-306]	[1-595]		[1-100]
Duration (median, p25- p75)	14 [14 - 14]	11 [8 - 11]	14 [7 - 14]	30 [5 - 30]		4 [2 - 4]
Duration (mean, sd)	15.4 (10.9)	21.3 (73.7)	16 (18.9)	21.3 (13.2)		5.8 (6.3)
Antibiotic	Oxytetracycline (J01AA06)					
Observations	187002	51425	14123	685	183	
Subjects	85577	46299	9095	648	167	
Duration (min-max)	[2-2876]	[1-3465]	[1-1715]	[5-32]	[1-1]	
Duration (median, p25- p75)	28 [7 - 28]	8 [4 - 8]	17 [12 - 17]	5 [5 - 7]	1 [1 - 1]	
Duration (mean, sd)	36.6 (46.5)	14 (66.7)	25.1 (36.2)	6.6 (3.5)	1 (0)	
Antibiotic	Pheneticillin (J01CE05)					
Observations			53650			
Subjects			46113			
Duration (min-max)			[1-810]			
Duration (median, p25- p75)			7 [7 - 7]			
Duration (mean, sd)			9 (17.4)			
Antibiotic	Piperacillin_tazobactam (J01CR05, J01CA12)					
Observations	119		9	108		22928
Subjects	88		8	102		17962
Duration (min-max)	[2-69]		[3-95]	[1-500]		[1-86]
Duration (median, p25- p75)	28 [28 - 28]		37 [18 - 37]	30 [30 - 30]		6 [3 - 6]
Duration (mean, sd)	28.2 (8.1)		47 (36)	41.5 (60.9)		6.9 (5.5)
Antibiotic	Vancomycin (A07AA09, J01XA01)					
Observations	1360	896	369	4519	3190	6081
Subjects	1199	801	305	3965	2677	5253
Duration (min-max)	[3-162]	[1-912]	[1-423]	[1-625]	[1-84]	[1-120]
Duration (median, p25- p75)	10 [10 - 10]	11 [6 - 11]	10 [7 - 10]	7 [5 - 10]	4 [2 - 4]	4 [2 - 4]
Duration (mean, sd)	12.3 (8.5)	18.8 (50.7)	27.6 (42.8)	10.2 (27.1)	6.1 (7)	5.4 (5.5)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
	Dissemination level: Public	

TABLE 4– INDICATION OF USE (IN TERMS OF INFECTIONS) OF TOP 5 OF MOST PRESCRIBED ANTIBIOTICS PER DATABASE

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
	Azithromycin											
N	130553		187076		1539019		15598		3448		674777	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	88305 (67.6%)	100387 (76.9%)	92755 (49.6%)	98912 (52.9%)	552522 (35.9%)	652043 (42.4%)	3092 (19.8%)	4478 (28.7%)	1483 (43%)	1476 (42.8%)	261315 (38.7%)	260032 (38.5%)
Surgical site infection	16 (0%)	27 (0%)			<5 (NA%)	<5 (NA%)	7 (0%)	12 (0.1%)	<5 (NA%)	<5 (NA%)		
Skin and soft tissue infection	733 (0.6%)	1048 (0.8%)	6571 (3.5%)	7516 (4%)	1799 (0.1%)	3023 (0.2%)	26 (0.2%)	37 (0.2%)	60 (1.7%)	66 (1.9%)	4317 (0.6%)	5328 (0.8%)
Pneumonia	190 (0.1%)	505 (0.4%)	5673 (3%)	6679 (3.6%)	20493 (1.3%)	24148 (1.6%)	3485 (22.3%)	3668 (23.5%)	621 (18%)	702 (20.4%)	15072 (2.2%)	16001 (2.4%)
Other infection	9196 (7%)	13224 (10.1%)	12734 (6.8%)	15564 (8.3%)	181100 (11.8%)	206766 (13.4%)	2064 (13.2%)	2435 (15.6%)	733 (21.3%)	851 (24.7%)	48580 (7.2%)	55441 (8.2%)
No indication	29039 (22.2%)	11480 (8.8%)	35545 (19%)	22720 (12.1%)	605973 (39.4%)	455087 (29.6%)	6746 (43.2%)	4392 (28.2%)	453 (13.1%)	332 (9.6%)	56418 (8.4%)	43561 (6.5%)
Lower respiratory tract infection other than pneumonia	463 (0.4%)	690 (0.5%)	11792 (6.3%)	13050 (7%)	141099 (9.2%)	162532 (10.6%)	1598 (10.2%)	2018 (12.9%)	177 (5.1%)	204 (5.9%)	217181 (32.2%)	223637 (33.1%)
Genitourinary tract infection	869 (0.7%)	991 (0.8%)	7438 (4%)	7678 (4.1%)	3636 (0.2%)	3977 (0.3%)	38 (0.2%)	40 (0.3%)	68 (2%)	69 (2%)	1854 (0.3%)	1929 (0.3%)
Gastrointestinal system infection	133 (0.1%)	165 (0.1%)	980 (0.5%)	1039 (0.6%)	8424 (0.5%)	16618 (1.1%)	87 (0.6%)	111 (0.7%)	226 (6.6%)	237 (6.9%)	1253 (0.2%)	1935 (0.3%)
Eye, ear, nose, throat or mouth infection	1943 (1.5%)	2979 (2.3%)	16988 (9.1%)	19690 (10.5%)	41479 (2.7%)	47408 (3.1%)	146 (0.9%)	358 (2.3%)	23 (0.7%)	26 (0.8%)	121514 (18%)	132609 (19.7%)
Central nervous system infection		<5 (NA%)	<5 (NA%)	5 (0%)	<5 (NA%)	7 (0%)	<5 (NA%)	7 (0%)	<5 (NA%)	<5 (NA%)	12 (0%)	19 (0%)
Catheter-related infection							7 (0%)	7 (0%)				
Cardiovascular system infection			10 (0%)	17 (0%)	<5 (NA%)	6 (0%)	11 (0.1%)	11 (0.1%)	7 (0.2%)	10 (0.3%)	13 (0%)	20 (0%)
Bone and joint infection	<5 (NA%)	8 (0%)	<5 (NA%)	5 (0%)	24 (0%)	50 (0%)	7 (0%)	8 (0.1%)	19 (0.6%)	23 (0.7%)	70 (0%)	111 (0%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Bloodstream infection	29 (0%)	71 (0.1%)	<5 (NA%)	<5 (NA%)	37 (0%)	82 (0%)	533 (3.4%)	565 (3.6%)	65 (1.9%)	80 (2.3%)	50 (0%)	73 (0%)
Cefaclor												
N	15857		856		4830		5		107		369117	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	11386 (71.8%)	11371 (71.7%)	385 (45%)	454 (53%)	1646 (34.1%)	1935 (40.1%)	<5 (NA%)	<5 (NA%)	10 (9.3%)	9 (8.4%)	154898 (42%)	147924 (40.1%)
Surgical site infection	32 (0.2%)	36 (0.2%)							9 (8.4%)	21 (19.6%)		
Skin and soft tissue infection	216 (1.4%)	281 (1.8%)	14 (1.6%)	19 (2.2%)	154 (3.2%)	195 (4%)			5 (4.7%)	20 (18.7%)	24442 (6.6%)	26130 (7.1%)
Pneumonia	22 (0.1%)	43 (0.3%)	39 (4.6%)	47 (5.5%)	14 (0.3%)	30 (0.6%)			<5 (NA%)	<5 (NA%)	15783 (4.3%)	16623 (4.5%)
Other infection	2287 (14.4%)	2906 (18.3%)	83 (9.7%)	108 (12.6%)	723 (15%)	851 (17.6%)		<5 (NA%)	36 (33.6%)	86 (80.4%)	62522 (16.9%)	69452 (18.8%)
No indication	1410 (8.9%)	602 (3.8%)	269 (31.4%)	148 (17.3%)	2134 (44.2%)	1571 (32.5%)	<5 (NA%)		57 (53.3%)	<5 (NA%)	27756 (7.5%)	21965 (6%)
Lower respiratory tract infection other than pneumonia	128 (0.8%)	172 (1.1%)	27 (3.2%)	41 (4.8%)	84 (1.7%)	161 (3.3%)				<5 (NA%)	66218 (17.9%)	72500 (19.6%)
Genitourinary tract infection	7 (0%)	8 (0.1%)	<5 (NA%)	<5 (NA%)							24 (0%)	29 (0%)
Gastrointestinal system infection	<5 (NA%)	<5 (NA%)			26 (0.5%)	79 (1.6%)			<5 (NA%)	<5 (NA%)	446 (0.1%)	840 (0.2%)
Eye, ear, nose, throat or mouth infection	421 (2.7%)	605 (3.8%)	48 (5.6%)	62 (7.2%)	80 (1.7%)	127 (2.6%)					62007 (16.8%)	73637 (19.9%)
Central nervous system infection											<5 (NA%)	7 (0%)
Catheter-related infection												
Cardiovascular system infection	<5 (NA%)	<5 (NA%)							<5 (NA%)	<5 (NA%)	<5 (NA%)	5 (0%)
Bone and joint infection		<5 (NA%)			<5 (NA%)	<5 (NA%)			26 (24.3%)	71 (66.4%)	93 (0%)	113 (0%)
Bloodstream infection	7 (0%)	13 (0.1%)				<5 (NA%)			<5 (NA%)	11 (10.3%)	166 (0%)	189 (0.1%)
Ceftriaxone												
N	992		3852		17680		18379		44490		2859	



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	820 (82.7%)	786 (79.2%)	853 (22.1%)	875 (22.7%)	3487 (19.7%)	4283 (24.2%)	4842 (26.3%)	4853 (26.4%)	14278 (32.1%)	14717 (33.1%)	807 (28.2%)	895 (31.3%)
Surgical site infection	<5 (NA%)	<5 (NA%)					43 (0.2%)	62 (0.3%)	99 (0.2%)	125 (0.3%)		
Skin and soft tissue infection	48 (4.8%)	59 (5.9%)	12 (0.3%)	29 (0.8%)	26 (0.1%)	34 (0.2%)	230 (1.3%)	261 (1.4%)	702 (1.6%)	877 (2%)	85 (3%)	103 (3.6%)
Pneumonia	9 (0.9%)	12 (1.2%)	6 (0.2%)	12 (0.3%)	464 (2.6%)	518 (2.9%)	3173 (17.3%)	3304 (18%)	8487 (19.1%)	9211 (20.7%)	153 (5.4%)	168 (5.9%)
Other infection	77 (7.8%)	110 (11.1%)	2638 (68.5%)	2719 (70.6%)	7614 (43.1%)	8657 (49%)	9258 (50.4%)	9811 (53.4%)	17447 (39.2%)	19520 (43.9%)	1175 (41.1%)	1277 (44.7%)
No indication	30 (3%)	6 (0.6%)	290 (7.5%)	171 (4.4%)	5669 (32.1%)	3721 (21%)	925 (5%)	261 (1.4%)	5568 (12.5%)	2775 (6.2%)	528 (18.5%)	292 (10.2%)
Lower respiratory tract infection other than pneumonia	<5 (NA%)	<5 (NA%)	<5 (NA%)	6 (0.2%)	267 (1.5%)	398 (2.3%)	1602 (8.7%)	1805 (9.8%)	1856 (4.2%)	2102 (4.7%)	155 (5.4%)	196 (6.9%)
Genitourinary tract infection	<5 (NA%)	<5 (NA%)	186 (4.8%)	204 (5.3%)	190 (1.1%)	206 (1.2%)	19 (0.1%)	20 (0.1%)	506 (1.1%)	529 (1.2%)	25 (0.9%)	31 (1.1%)
Gastrointestinal system infection			<5 (NA%)	<5 (NA%)	78 (0.4%)	152 (0.9%)	303 (1.6%)	338 (1.8%)	514 (1.2%)	596 (1.3%)	21 (0.7%)	31 (1.1%)
Eye, ear, nose, throat or mouth infection		<5 (NA%)	24 (0.6%)	46 (1.2%)	108 (0.6%)	158 (0.9%)	76 (0.4%)	92 (0.5%)	97 (0.2%)	115 (0.3%)	61 (2.1%)	99 (3.5%)
Central nervous system infection		<5 (NA%)			<5 (NA%)	<5 (NA%)	50 (0.3%)	55 (0.3%)	156 (0.4%)	178 (0.4%)	18 (0.6%)	18 (0.6%)
Catheter-related infection							19 (0.1%)	20 (0.1%)				
Cardiovascular system infection		<5 (NA%)	7 (0.2%)	10 (0.3%)	<5 (NA%)	<5 (NA%)	99 (0.5%)	114 (0.6%)	360 (0.8%)	402 (0.9%)		<5 (NA%)
Bone and joint infection	5 (0.5%)	12 (1.2%)	<5 (NA%)	<5 (NA%)	15 (0.1%)	17 (0.1%)	124 (0.7%)	137 (0.7%)	585 (1.3%)	747 (1.7%)	<5 (NA%)	<5 (NA%)
Bloodstream infection	<5 (NA%)	9 (0.9%)	<5 (NA%)	<5 (NA%)	43 (0.2%)	57 (0.3%)	2426 (13.2%)	2586 (14.1%)	3970 (8.9%)	4527 (10.2%)	22 (0.8%)	27 (0.9%)
Cefuroxime												
N	4640		1748		576002		2702		1647		929894	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	3490 (75.2%)	3599 (77.6%)	611 (35%)	695 (39.8%)	148883 (25.8%)	195625 (34%)	342 (12.7%)	811 (30%)	1063 (64.5%)	1072 (65.1%)	416800 (44.8%)	419730 (45.1%)
Surgical site infection	22 (0.5%)	24 (0.5%)			8 (0%)	8 (0%)		<5 (NA%)	8 (0.5%)	21 (1.3%)		



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Skin and soft tissue infection	89 (1.9%)	114 (2.5%)	30 (1.7%)	39 (2.2%)	1072 (0.2%)	1578 (0.3%)	<5 (NA%)	6 (0.2%)	18 (1.1%)	24 (1.5%)	29063 (3.1%)	31068 (3.3%)
Pneumonia	7 (0.2%)	10 (0.2%)	23 (1.3%)	37 (2.1%)	2214 (0.4%)	3179 (0.6%)	<5 (NA%)	12 (0.4%)	83 (5%)	107 (6.5%)	24750 (2.7%)	26164 (2.8%)
Other infection	453 (9.8%)	633 (13.6%)	635 (36.3%)	705 (40.3%)	145638 (25.3%)	178899 (31.1%)	232 (8.6%)	912 (33.8%)	243 (14.8%)	342 (20.8%)	118851 (12.8%)	131321 (14.1%)
No indication	532 (11.5%)	197 (4.2%)	436 (24.9%)	255 (14.6%)	265355 (46.1%)	179778 (31.2%)	2117 (78.3%)	934 (34.6%)	184 (11.2%)	66 (4%)	84342 (9.1%)	59703 (6.4%)
Lower respiratory tract infection other than pneumonia	14 (0.3%)	21 (0.5%)	14 (0.8%)	23 (1.3%)	9378 (1.6%)	12982 (2.3%)	6 (0.2%)	26 (1%)	16 (1%)	21 (1.3%)	220230 (23.7%)	228761 (24.6%)
Genitourinary tract infection	5 (0.1%)	7 (0.2%)	<5 (NA%)	5 (0.3%)	50 (0%)	88 (0%)		<5 (NA%)			263 (0%)	305 (0%)
Gastrointestinal system infection		<5 (NA%)			1647 (0.3%)	3916 (0.7%)	<5 (NA%)	<5 (NA%)	<5 (NA%)	6 (0.4%)	811 (0.1%)	1494 (0.2%)
Eye, ear, nose, throat or mouth infection	42 (0.9%)	66 (1.4%)	17 (1%)	28 (1.6%)	3497 (0.6%)	5008 (0.9%)	<5 (NA%)	15 (0.6%)	6 (0.4%)	7 (0.4%)	91767 (9.9%)	104105 (11.2%)
Central nervous system infection					<5 (NA%)	6 (0%)			<5 (NA%)	<5 (NA%)	44 (0%)	57 (0%)
Catheter-related infection												
Cardiovascular system infection		<5 (NA%)	<5 (NA%)	<5 (NA%)	<5 (NA%)	<5 (NA%)			15 (0.9%)	22 (1.3%)	25 (0%)	34 (0%)
Bone and joint infection			<5 (NA%)	5 (0.3%)	93 (0%)	128 (0%)		<5 (NA%)	178 (10.8%)	232 (14.1%)	517 (0.1%)	654 (0.1%)
Bloodstream infection	<5 (NA%)	5 (0.1%)			434 (0.1%)	648 (0.1%)	10 (0.4%)	41 (1.5%)	54 (3.3%)	86 (5.2%)	583 (0.1%)	773 (0.1%)
Ciprofloxacin												
N	369519		145789		1258448		22747		8769		677383	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	292050 (79%)	294328 (79.7%)	59916 (41.1%)	66800 (45.8%)	368532(29.3%)	490352(39%)	6827 (30%)	9195 (40.4%)	2821 (32.2%)	2998 (34.2%)	299247 (44.2%)	308557 (45.6%)
Surgical site infection	541 (0.1%)	784 (0.2%)			43(0%)	49(0%)	169 (0.7%)	376 (1.7%)	33 (0.4%)	64 (0.7%)		
Skin and soft tissue infection	2500 (0.7%)	3946 (1.1%)	1164 (0.8%)	2128 (1.5%)	1893(0.2%)	2628(0.2%)	171 (0.8%)	281 (1.2%)	148 (1.7%)	264 (3%)	7031 (1%)	8380 (1.2%)
Pneumonia	199 (0.1%)	630 (0.2%)	1681 (1.2%)	2499 (1.7%)	1333(0.1%)	2614(0.2%)	313 (1.4%)	603 (2.7%)	846 (9.6%)	1151 (13.1%)	6591 (1%)	7787 (1.1%)
Other infection	41920 (11.3%)	53819 (14.6%)	50050 (34.3%)	54829 (37.6%)	252445(20.1%)	301138(23.9%)	5307 (23.3%)	7833 (34.4%)	3414 (38.9%)	4577 (52.2%)	212146 (31.3%)	223463 (33%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
No indication	28707 (7.8%)	11412 (3.1%)	30968 (21.2%)	17478 (12%)	595119(47.3%)	415214(33%)	9616 (42.3%)	4279 (18.8%)	1820 (20.8%)	370 (4.2%)	88549 (13.1%)	61482 (9.1%)
Lower respiratory tract infection other than pneumonia	674 (0.2%)	1091 (0.3%)	1110 (0.8%)	1777 (1.2%)	10651(0.8%)	16038(1.3%)	724 (3.2%)	1161 (5.1%)	192 (2.2%)	296 (3.4%)	56918 (8.4%)	64124 (9.5%)
Genitourinary tract infection	51 (0%)	110 (0%)	72 (0%)	130 (0.1%)	212(0%)	302(0%)	10 (0%)	11 (0%)	62 (0.7%)	80 (0.9%)	266 (0%)	341 (0.1%)
Gastrointestinal system infection	1664 (0.5%)	1789 (0.5%)	696 (0.5%)	752 (0.5%)	28075(2.2%)	33002(2.6%)	367 (1.6%)	486 (2.1%)	102 (1.2%)	145 (1.7%)	3143 (0.5%)	3724 (0.5%)
Eye, ear, nose, throat or mouth infection	1346 (0.4%)	2660 (0.7%)	1087 (0.7%)	2229 (1.5%)	2179(0.2%)	3759(0.3%)	35 (0.2%)	59 (0.3%)	17 (0.2%)	29 (0.3%)	21776 (3.2%)	27463 (4.1%)
Central nervous system infection	5 (0%)	5 (0%)	7 (0%)	13 (0%)	11(0%)	15(0%)	6 (0%)	10 (0%)	13 (0.1%)	23 (0.3%)	26 (0%)	43 (0%)
Catheter-related infection					6(0%)	6(0%)	13 (0.1%)	21 (0.1%)				
Cardiovascular system infection	37 (0%)	63 (0%)	11 (0%)	25 (0%)	<5(NA%)	6(0%)	12 (0.1%)	24 (0.1%)	34 (0.4%)	41 (0.5%)	13 (0%)	22 (0%)
Bone and joint infection	185 (0.1%)	325 (0.1%)	45 (0%)	70 (0%)	550(0%)	762(0.1%)	127 (0.6%)	195 (0.9%)	393 (4.5%)	614 (7%)	323 (0%)	447 (0.1%)
Bloodstream infection	279 (0.1%)	799 (0.2%)	18 (0%)	26 (0%)	841(0.1%)	1282(0.1%)	1330 (5.8%)	1900 (8.4%)	614 (7%)	906 (10.3%)	857 (0.1%)	1121 (0.2%)
Clarithromycin												
N	1288110		83370		488454		1705		821		329386	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	935330 (72.6%)	927478 (72%)	43438 (52.1%)	46715 (56%)	132686 (27.2%)	163166 (33.4%)	186 (10.9%)	494 (29%)	231 (28.1%)	296 (36.1%)	117856 (35.8%)	118609 (36%)
Surgical site infection	2461 (0.2%)	2839 (0.2%)				<5 (NA%)		<5 (NA%)	5 (0.6%)	7 (0.9%)		
Skin and soft tissue infection	41354 (3.2%)	46881 (3.6%)	9332 (11.2%)	10184 (12.2%)	1211 (0.2%)	1462 (0.3%)	<5 (NA%)	<5 (NA%)	16 (1.9%)	24 (2.9%)	2378 (0.7%)	2944 (0.9%)
Pneumonia	2392 (0.2%)	4195 (0.3%)	3321 (4%)	3774 (4.5%)	7526 (1.5%)	8284 (1.7%)	<5 (NA%)	14 (0.8%)	229 (27.9%)	257 (31.3%)	17232 (5.2%)	17967 (5.5%)
Other infection	183889 (14.3%)	218929 (17%)	2927 (3.5%)	4086 (4.9%)	149214 (30.5%)	161903 (33.1%)	41 (2.4%)	103 (6%)	158 (19.2%)	219 (26.7%)	42076 (12.8%)	46650 (14.2%)
No indication	71307 (5.5%)	27644 (2.1%)	16431 (19.7%)	10014 (12%)	164668 (33.7%)	116199 (23.8%)	1461 (85.7%)	1019 (59.8%)	199 (24.2%)	55 (6.7%)	27582 (8.4%)	18484 (5.6%)
Lower respiratory tract infection other than pneumonia	13676 (1.1%)	17050 (1.3%)	4870 (5.8%)	5497 (6.6%)	25897 (5.3%)	30388 (6.2%)	11 (0.6%)	57 (3.3%)	40 (4.9%)	51 (6.2%)	109213 (33.2%)	113802 (34.5%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Genitourinary tract infection	355 (0%)	520 (0%)	19 (0%)	45 (0.1%)	21 (0%)	37 (0%)			<5 (NA%)	<5 (NA%)	37 (0%)	46 (0%)
Gastrointestinal system infection	3629 (0.3%)	4143 (0.3%)	123 (0.1%)	143 (0.2%)	1895 (0.4%)	4466 (0.9%)	<5 (NA%)	<5 (NA%)	6 (0.7%)	8 (1%)	2070 (0.6%)	2553 (0.8%)
Eye, ear, nose, throat or mouth infection	38770 (3%)	51830 (4%)	4660 (5.6%)	5741 (6.9%)	9072 (1.9%)	10420 (2.1%)	8 (0.5%)	37 (2.2%)	5 (0.6%)	5 (0.6%)	40019 (12.1%)	45868 (13.9%)
Central nervous system infection	<5 (NA%)	12 (0%)	<5 (NA%)	<5 (NA%)		<5 (NA%)					7 (0%)	9 (0%)
Catheter-related infection												
Cardiovascular system infection	93 (0%)	128 (0%)	5 (0%)	9 (0%)	<5 (NA%)	<5 (NA%)			<5 (NA%)	<5 (NA%)	9 (0%)	12 (0%)
Bone and joint infection	89 (0%)	146 (0%)	13 (0%)	16 (0%)	18 (0%)	21 (0%)		<5 (NA%)	17 (2.1%)	22 (2.7%)	44 (0%)	77 (0%)
Bloodstream infection	137 (0%)	455 (0%)	<5 (NA%)	<5 (NA%)	10 (0%)	22 (0%)	<5 (NA%)	5 (0.3%)	16 (1.9%)	22 (2.7%)	65 (0%)	85 (0%)
Erythromycin												
N	747601		10660		56581		1725		2943		136769	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	538409 (72%)	546568 (73.1%)	5351 (50.2%)	5881 (55.2%)	25152 (44.5%)	29453 (52.1%)	826 (47.9%)	930 (53.9%)	1681 (57.1%)	1761 (59.8%)	58183 (42.5%)	57596 (42.1%)
Surgical site infection	1709 (0.2%)	1937 (0.3%)					16 (0.9%)	40 (2.3%)	<5 (NA%)	<5 (NA%)		
Skin and soft tissue infection	38053 (5.1%)	41650 (5.6%)	902 (8.5%)	983 (9.2%)	754 (1.3%)	838 (1.5%)	13 (0.8%)	35 (2%)	28 (1%)	42 (1.4%)	4568 (3.3%)	5239 (3.8%)
Pneumonia	250 (0%)	464 (0.1%)	268 (2.5%)	310 (2.9%)	199 (0.4%)	257 (0.5%)	59 (3.4%)	133 (7.7%)	149 (5.1%)	230 (7.8%)	13337 (9.8%)	13677 (10%)
Other infection	61782 (8.3%)	73264 (9.8%)	407 (3.8%)	568 (5.3%)	3851 (6.8%)	4868 (8.6%)	267 (15.5%)	496 (28.8%)	699 (23.8%)	957 (32.5%)	13264 (9.7%)	16007 (11.7%)
No indication	72503 (9.7%)	43737 (5.9%)	2945 (27.6%)	2033 (19.1%)	23029 (40.7%)	16852 (29.8%)	539 (31.2%)	151 (8.8%)	462 (15.7%)	86 (2.9%)	19173 (14%)	16534 (12.1%)
Lower respiratory tract infection other than pneumonia	5587 (0.7%)	6563 (0.9%)	337 (3.2%)	397 (3.7%)	1780 (3.1%)	2127 (3.8%)	59 (3.4%)	110 (6.4%)	38 (1.3%)	57 (1.9%)	32934 (24.1%)	34903 (25.5%)
Genitourinary tract infection	350 (0%)	456 (0.1%)	13 (0.1%)	21 (0.2%)	32 (0.1%)	40 (0.1%)		<5 (NA%)	7 (0.2%)	11 (0.4%)	323 (0.2%)	337 (0.2%)
Gastrointestinal system infection	1485 (0.2%)	1609 (0.2%)	97 (0.9%)	105 (1%)	704 (1.2%)	1176 (2.1%)	19 (1.1%)	36 (2.1%)	14 (0.5%)	21 (0.7%)	593 (0.4%)	705 (0.5%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Eye, ear, nose, throat or mouth infection	29979 (4%)	37396 (5%)	563 (5.3%)	698 (6.5%)	1282 (2.3%)	1435 (2.5%)	<5 (NA%)	5 (0.3%)	<5 (NA%)	6 (0.2%)	16674 (12.2%)	21058 (15.4%)
Central nervous system infection		<5 (NA%)			<5 (NA%)	<5 (NA%)		<5 (NA%)	6 (0.2%)	6 (0.2%)	<5 (NA%)	<5 (NA%)
Catheter-related infection							<5 (NA%)	8 (0.5%)				
Cardiovascular system infection	55 (0%)	71 (0%)	<5 (NA%)	<5 (NA%)			<5 (NA%)	<5 (NA%)	13 (0.4%)	15 (0.5%)	<5 (NA%)	<5 (NA%)
Bone and joint infection	51 (0%)	80 (0%)		<5 (NA%)	9 (0%)	10 (0%)	<5 (NA%)	7 (0.4%)	24 (0.8%)	32 (1.1%)	8 (0%)	12 (0%)
Bloodstream infection	33 (0%)	129 (0%)			<5 (NA%)	6 (0%)	98 (5.7%)	208 (12.1%)	131 (4.5%)	208 (7.1%)	11 (0%)	13 (0%)
Fosfomycin												
N	11222		116533		1896813		15575		1157		404127	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	9410 (83.9%)	9210 (82.1%)	37548 (32.2%)	41997 (36%)	441597 (23.3%)	552243 (29.1%)	3338 (21.4%)	5770 (37%)	322 (27.8%)	342 (29.6%)	153988 (38.1%)	158543 (39.2%)
Surgical site infection		<5 (NA%)			<5 (NA%)	<5 (NA%)	6 (0%)	19 (0.1%)	7 (0.6%)	11 (1%)		
Skin and soft tissue infection	8 (0.1%)	42 (0.4%)	197 (0.2%)	741 (0.6%)	301 (0%)	864 (0%)	8 (0.1%)	17 (0.1%)	7 (0.6%)	15 (1.3%)	326 (0.1%)	709 (0.2%)
Pneumonia	<5 (NA%)	16 (0.1%)	109 (0.1%)	504 (0.4%)	414 (0%)	1453 (0.1%)	65 (0.4%)	133 (0.9%)	17 (1.5%)	35 (3%)	172 (0%)	481 (0.1%)
Other infection	1263 (11.3%)	1803 (16.1%)	52164 (44.8%)	57361 (49.2%)	794850 (41.9%)	840011 (44.3%)	2646 (17%)	4961 (31.9%)	519 (44.9%)	664 (57.4%)	193928 (48%)	198842 (49.2%)
No indication	528 (4.7%)	131 (1.2%)	26437 (22.7%)	15950 (13.7%)	655084 (34.5%)	491084 (25.9%)	9510 (61.1%)	4651 (29.9%)	297 (25.7%)	125 (10.8%)	53815 (13.3%)	42152 (10.4%)
Lower respiratory tract infection other than pneumonia	<5 (NA%)	<5 (NA%)	135 (0.1%)	531 (0.5%)	2772 (0.1%)	9635 (0.5%)	139 (0.9%)	288 (1.8%)	6 (0.5%)	17 (1.5%)	1652 (0.4%)	4116 (1%)
Genitourinary tract infection	<5 (NA%)	<5 (NA%)	77 (0.1%)	159 (0.1%)	92 (0%)	224 (0%)	<5 (NA%)	5 (0%)	<5 (NA%)	5 (0.4%)	218 (0.1%)	266 (0.1%)
Gastrointestinal system infection	<5 (NA%)	<5 (NA%)	8 (0%)	28 (0%)	5051 (0.3%)	11353 (0.6%)	29 (0.2%)	55 (0.4%)	11 (1%)	16 (1.4%)	250 (0.1%)	470 (0.1%)
Eye, ear, nose, throat or mouth infection	7 (0.1%)	27 (0.2%)	349 (0.3%)	1178 (1%)	1099 (0.1%)	3884 (0.2%)	5 (0%)	20 (0.1%)	<5 (NA%)	<5 (NA%)	3166 (0.8%)	6232 (1.5%)
Central nervous system infection					<5 (NA%)	<5 (NA%)		<5 (NA%)	15 (1.3%)	19 (1.6%)	6 (0%)	12 (0%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Catheter-related infection					<5 (NA%)	<5 (NA%)		<5 (NA%)				
Cardiovascular system infection			<5 (NA%)	7 (0%)	6 (0%)	11 (0%)	<5 (NA%)	<5 (NA%)	12 (1%)	13 (1.1%)	<5 (NA%)	<5 (NA%)
Bone and joint infection	<5 (NA%)	<5 (NA%)	<5 (NA%)	8 (0%)	26 (0%)	64 (0%)	6 (0%)	13 (0.1%)	36 (3.1%)	61 (5.3%)	19 (0%)	40 (0%)
Bloodstream infection	9 (0.1%)	41 (0.4%)	<5 (NA%)	7 (0%)	121 (0%)	361 (0%)	88 (0.6%)	232 (1.5%)	31 (2.7%)	49 (4.2%)	56 (0%)	115 (0%)
Levofloxacin												
N	10593		7660		891616		22843		6008		224573	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	8087 (76.3%)	7936 (74.9%)	4887 (63.8%)	5494 (71.7%)	176313 (19.8%)	254281 (28.5%)	4352 (19.1%)	5801 (25.4%)	1988 (33.1%)	2052 (34.2%)	83930 (37.4%)	86629 (38.6%)
Surgical site infection	13 (0.1%)	19 (0.2%)			22 (0%)	25 (0%)	41 (0.2%)	90 (0.4%)	170 (2.8%)	301 (5%)		
Skin and soft tissue infection	47 (0.4%)	79 (0.7%)	38 (0.5%)	67 (0.9%)	414 (0%)	660 (0.1%)	54 (0.2%)	77 (0.3%)	134 (2.2%)	237 (3.9%)	2566 (1.1%)	3074 (1.4%)
Pneumonia	108 (1%)	228 (2.2%)	142 (1.9%)	190 (2.5%)	46113 (5.2%)	51550 (5.8%)	3766 (16.5%)	4264 (18.7%)	834 (13.9%)	977 (16.3%)	10311 (4.6%)	11016 (4.9%)
Other infection	1339 (12.6%)	1920 (18.1%)	358 (4.7%)	549 (7.2%)	161620 (18.1%)	189231 (21.2%)	3331 (14.6%)	4451 (19.5%)	2037 (33.9%)	3011 (50.1%)	40102 (17.9%)	44409 (19.8%)
No indication	899 (8.5%)	283 (2.7%)	2066 (27%)	1149 (15%)	430673 (48.3%)	308408 (34.6%)	8122 (35.6%)	4553 (19.9%)	1274 (21.2%)	148 (2.5%)	29056 (12.9%)	19266 (8.6%)
Lower respiratory tract infection other than pneumonia	53 (0.5%)	89 (0.8%)	75 (1%)	109 (1.4%)	83718 (9.4%)	100296 (11.2%)	5607 (24.5%)	6529 (28.6%)	163 (2.7%)	204 (3.4%)	58875 (26.2%)	62243 (27.7%)
Genitourinary tract infection	<5 (NA%)	<5 (NA%)	6 (0.1%)	8 (0.1%)	26 (0%)	52 (0%)	<5 (NA%)	<5 (NA%)	20 (0.3%)	26 (0.4%)	90 (0%)	115 (0.1%)
Gastrointestinal system infection	12 (0.1%)	17 (0.2%)	<5 (NA%)	<5 (NA%)	1589 (0.2%)	3832 (0.4%)	69 (0.3%)	108 (0.5%)	25 (0.4%)	33 (0.5%)	239 (0.1%)	423 (0.2%)
Eye, ear, nose, throat or mouth infection	59 (0.6%)	123 (1.2%)	114 (1.5%)	172 (2.2%)	5443 (0.6%)	7704 (0.9%)	152 (0.7%)	267 (1.2%)	65 (1.1%)	67 (1.1%)	14172 (6.3%)	16935 (7.5%)
Central nervous system infection		<5 (NA%)			7 (0%)	11 (0%)	7 (0%)	18 (0.1%)	12 (0.2%)	22 (0.4%)	13 (0%)	21 (0%)
Catheter-related infection					25 (0%)	27 (0%)	7 (0%)	9 (0%)				
Cardiovascular system infection		<5 (NA%)	<5 (NA%)	<5 (NA%)	<5 (NA%)	12 (0%)	13 (0.1%)	18 (0.1%)	85 (1.4%)	132 (2.2%)	8 (0%)	12 (0%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Bone and joint infection	10 (0.1%)	25 (0.2%)	<5 (NA%)	5 (0.1%)	559 (0.1%)	861 (0.1%)	49 (0.2%)	118 (0.5%)	866 (14.4%)	1424 (23.7%)	168 (0.1%)	211 (0.1%)
Bloodstream infection	15 (0.1%)	34 (0.3%)	<5 (NA%)	<5 (NA%)	241 (0%)	411 (0%)	745 (3.3%)	964 (4.2%)	410 (6.8%)	641 (10.7%)	288 (0.1%)	365 (0.2%)
Lymecycline												
N	313052								54			
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	218010 (69.6%)	237556 (75.9%)							46 (85.2%)	45 (83.3%)		
Surgical site infection	13 (0%)	36 (0%)										
Skin and soft tissue infection	5054 (1.6%)	6420 (2.1%)							<5 (NA%)	<5 (NA%)		
Pneumonia	<5 (NA%)	8 (0%)										
Other infection	2072 (0.7%)	3330 (1.1%)							<5 (NA%)	<5 (NA%)		
No indication	87114 (27.8%)	64514 (20.6%)							<5 (NA%)	<5 (NA%)		
Lower respiratory tract infection other than pneumonia	68 (0%)	113 (0%)										
Genitourinary tract infection	96 (0%)	135 (0%)										
Gastrointestinal system infection	10 (0%)	17 (0%)										
Eye, ear, nose, throat or mouth infection	716 (0.2%)	1158 (0.4%)										
Central nervous system infection												
Catheter-related infection												
Cardiovascular system infection												
Bone and joint infection	<5 (NA%)	<5 (NA%)										
Bloodstream infection	<5 (NA%)	9 (0%)										



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Ofloxacin												
N	26405		5937		2505				9316		173681	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	23194 (87.8%)	23466 (88.9%)	2431 (40.9%)	3070 (51.7%)	696 (27.8%)	924 (36.9%)			3385 (36.3%)	3668 (39.4%)	86459 (49.8%)	84147 (48.4%)
Surgical site infection	15 (0.1%)	19 (0.1%)							68 (0.7%)	115 (1.2%)		
Skin and soft tissue infection	53 (0.2%)	104 (0.4%)	12 (0.2%)	36 (0.6%)	<5 (NA%)	<5 (NA%)			174 (1.9%)	270 (2.9%)	1059 (0.6%)	1721 (1%)
Pneumonia	5 (0%)	18 (0.1%)	19 (0.3%)	33 (0.6%)	5 (0.2%)	11 (0.4%)			363 (3.9%)	532 (5.7%)	674 (0.4%)	1107 (0.6%)
Other infection	1335 (5.1%)	1744 (6.6%)	1096 (18.5%)	1247 (21%)	453 (18.1%)	550 (22%)			3345 (35.9%)	4393 (47.2%)	24350 (14%)	28006 (16.1%)
No indication	1740 (6.6%)	926 (3.5%)	2198 (37%)	1353 (22.8%)	1311 (52.3%)	966 (38.6%)			2118 (22.7%)	667 (7.2%)	18445 (10.6%)	14035 (8.1%)
Lower respiratory tract infection other than pneumonia	16 (0.1%)	32 (0.1%)	38 (0.6%)	56 (0.9%)	18 (0.7%)	27 (1.1%)			154 (1.7%)	203 (2.2%)	8226 (4.7%)	11405 (6.6%)
Genitourinary tract infection	25 (0.1%)	47 (0.2%)	110 (1.9%)	123 (2.1%)	6 (0.2%)	8 (0.3%)			91 (1%)	102 (1.1%)	22 (0%)	34 (0%)
Gastrointestinal system infection	<5 (NA%)	<5 (NA%)	<5 (NA%)	<5 (NA%)	19 (0.8%)	27 (1.1%)			73 (0.8%)	93 (1%)	230 (0.1%)	439 (0.3%)
Eye, ear, nose, throat or mouth infection	40 (0.2%)	104 (0.4%)	76 (1.3%)	111 (1.9%)	<5 (NA%)	<5 (NA%)			10 (0.1%)	15 (0.2%)	40698 (23.4%)	44008 (25.3%)
Central nervous system infection									12 (0.1%)	18 (0.2%)	5 (0%)	11 (0%)
Catheter-related infection												
Cardiovascular system infection									54 (0.6%)	88 (0.9%)	<5 (NA%)	8 (0%)
Bone and joint infection									515 (5.5%)	779 (8.4%)	13 (0%)	29 (0%)
Bloodstream infection	<5 (NA%)	12 (0%)	<5 (NA%)	<5 (NA%)					607 (6.5%)	882 (9.5%)	23 (0%)	39 (0%)
Oxytetracycline												
N	187002		14123		51425		183				685	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Unknown indication	112563 (60.2%)	128286 (68.6%)	6870 (48.6%)	8784 (62.2%)	31126 (60.5%)	34581 (67.2%)	14 (7.7%)	57 (31.1%)			263 (38.4%)	268 (39.1%)
Surgical site infection	33 (0%)	61 (0%)										
Skin and soft tissue infection	2307 (1.2%)	2900 (1.6%)	104 (0.7%)	191 (1.4%)	95 (0.2%)	131 (0.3%)					<5 (NA%)	<5 (NA%)
Pneumonia	30 (0%)	62 (0%)	16 (0.1%)	31 (0.2%)	8 (0%)	28 (0.1%)					<5 (NA%)	<5 (NA%)
Other infection	4816 (2.6%)	6490 (3.5%)	183 (1.3%)	351 (2.5%)	612 (1.2%)	1123 (2.2%)					21 (3.1%)	30 (4.4%)
No indication	64333 (34.4%)	45901 (24.5%)	6838 (48.4%)	4552 (32.2%)	18877 (36.7%)	14453 (28.1%)	169 (92.3%)	126 (68.9%)			60 (8.8%)	40 (5.8%)
Lower respiratory tract infection other than pneumonia	1002 (0.5%)	1142 (0.6%)	17 (0.1%)	46 (0.3%)	156 (0.3%)	313 (0.6%)					299 (43.6%)	306 (44.7%)
Genitourinary tract infection	42 (0%)	56 (0%)	<5 (NA%)	6 (0%)		<5 (NA%)						
Gastrointestinal system infection	17 (0%)	35 (0%)	<5 (NA%)	<5 (NA%)	87 (0.2%)	232 (0.5%)					<5 (NA%)	<5 (NA%)
Eye, ear, nose, throat or mouth infection	2008 (1.1%)	2510 (1.3%)	117 (0.8%)	216 (1.5%)	484 (0.9%)	637 (1.2%)					68 (9.9%)	75 (10.9%)
Central nervous system infection												
Catheter-related infection												
Cardiovascular system infection	6 (0%)	7 (0%)		<5 (NA%)	<5 (NA%)	<5 (NA%)						
Bone and joint infection	<5 (NA%)	8 (0%)			<5 (NA%)	<5 (NA%)					<5 (NA%)	<5 (NA%)
Bloodstream infection		<5 (NA%)			<5 (NA%)	<5 (NA%)						
Pheneticillin												
N			53650									
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication			41310 (77%)	41271 (76.9%)								
Surgical site infection												



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Skin and soft tissue infection			3749 (7%)	3934 (7.3%)								
Pneumonia			30 (0.1%)	85 (0.2%)								
Other infection			625 (1.2%)	1191 (2.2%)								
No indication			4676 (8.7%)	3523 (6.6%)								
Lower respiratory tract infection other than pneumonia			73 (0.1%)	136 (0.3%)								
Genitourinary tract infection			30 (0.1%)	76 (0.1%)								
Gastrointestinal system infection			<5 (NA%)	9 (0%)								
Eye, ear, nose, throat or mouth infection			5437 (10.1%)	5907 (11%)								
Central nervous system infection												
Catheter-related infection												
Cardiovascular system infection			<5 (NA%)	<5 (NA%)								
Bone and joint infection			<5 (NA%)	5 (0%)								
Bloodstream infection												
Piperacillin_tazobactam												
N	119		9				12701		22928		108	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	89 (74.8%)	80 (67.2%)	<5 (NA%)	<5 (NA%)			2933 (23.1%)	3290 (25.9%)	4530 (19.8%)	4694 (20.5%)	47 (43.5%)	54 (50%)
Surgical site infection	<5 (NA%)	<5 (NA%)					122 (1%)	199 (1.6%)	428 (1.9%)	498 (2.2%)		
Skin and soft tissue infection		<5 (NA%)	<5 (NA%)	<5 (NA%)			180 (1.4%)	231 (1.8%)	832 (3.6%)	1088 (4.7%)		
Pneumonia	7 (5.9%)	10 (8.4%)		<5 (NA%)			1890 (14.9%)	2534 (20%)	3945 (17.2%)	4989 (21.8%)	17 (15.7%)	19 (17.6%)
Other infection	18 (15.1%)	28 (23.5%)	<5 (NA%)	<5 (NA%)			4717 (37.1%)	6311 (49.7%)	11853 (51.7%)	14508 (63.3%)	14 (13%)	19 (17.6%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
No indication	<5 (NA%)		<5 (NA%)	<5 (NA%)			2783 (21.9%)	456 (3.6%)	3936 (17.2%)	838 (3.7%)	28 (25.9%)	14 (13%)
Lower respiratory tract infection other than pneumonia							1805 (14.2%)	2491 (19.6%)	602 (2.6%)	869 (3.8%)	<5 (NA%)	6 (5.6%)
Genitourinary tract infection							12 (0.1%)	13 (0.1%)	216 (0.9%)	262 (1.1%)		
Gastrointestinal system infection							193 (1.5%)	290 (2.3%)	252 (1.1%)	365 (1.6%)	<5 (NA%)	<5 (NA%)
Eye, ear, nose, throat or mouth infection	<5 (NA%)	<5 (NA%)	<5 (NA%)	<5 (NA%)			40 (0.3%)	57 (0.4%)	19 (0.1%)	30 (0.1%)	<5 (NA%)	<5 (NA%)
Central nervous system infection							12 (0.1%)	20 (0.2%)	29 (0.1%)	44 (0.2%)		
Catheter-related infection							19 (0.1%)	32 (0.3%)				
Cardiovascular system infection							42 (0.3%)	58 (0.5%)	139 (0.6%)	196 (0.9%)		
Bone and joint infection							112 (0.9%)	136 (1.1%)	2197 (9.6%)	2589 (11.3%)	<5 (NA%)	<5 (NA%)
Bloodstream infection	<5 (NA%)	6 (5%)					1825 (14.4%)	2326 (18.3%)	2845 (12.4%)	3668 (16%)	6 (5.6%)	6 (5.6%)
Vancomycin												
N	1360		369		896		3190		6081		4519	
	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]	[-7, 7]	[-30, 7]
Unknown indication	1078 (79.3%)	950 (69.9%)	197 (53.4%)	232 (62.9%)	157 (17.5%)	261 (29.1%)	1057 (33.1%)	1229 (38.5%)	1644 (27%)	1691 (27.8%)	1340 (29.7%)	1449 (32.1%)
Surgical site infection	<5 (NA%)	5 (0.4%)					40 (1.3%)	79 (2.5%)	201 (3.3%)	226 (3.7%)		
Skin and soft tissue infection	<5 (NA%)	11 (0.8%)	5 (1.4%)	9 (2.4%)	<5 (NA%)	<5 (NA%)	33 (1%)	61 (1.9%)	198 (3.3%)	240 (3.9%)	18 (0.4%)	53 (1.2%)
Pneumonia	<5 (NA%)	5 (0.4%)	<5 (NA%)	<5 (NA%)	<5 (NA%)	<5 (NA%)	94 (2.9%)	193 (6.1%)	231 (3.8%)	375 (6.2%)	94 (2.1%)	181 (4%)
Other infection	42 (3.1%)	89 (6.5%)	19 (5.1%)	34 (9.2%)	82 (9.2%)	106 (11.8%)	731 (22.9%)	1216 (38.1%)	2999 (49.3%)	3662 (60.2%)	502 (11.1%)	749 (16.6%)
No indication	35 (2.6%)	5 (0.4%)	128 (34.7%)	67 (18.2%)	503 (56.1%)	348 (38.8%)	1048 (32.9%)	304 (9.5%)	914 (15%)	155 (2.5%)	910 (20.1%)	385 (8.5%)
Lower respiratory tract infection other than pneumonia			<5 (NA%)	<5 (NA%)	<5 (NA%)	5 (0.6%)	112 (3.5%)	216 (6.8%)	57 (0.9%)	101 (1.7%)	52 (1.2%)	146 (3.2%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder,
Talita Duarte Salles, Dani Prieto Alhambra,
Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

	CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Genitourinary tract infection								<5 (NA%)	12 (0.2%)	20 (0.3%)		<5 (NA%)
Gastrointestinal system infection	203 (14.9%)	317 (23.3%)	18 (4.9%)	23 (6.2%)	149 (16.6%)	182 (20.3%)	359 (11.3%)	545 (17.1%)	313 (5.1%)	452 (7.4%)	1845 (40.8%)	2087 (46.2%)
Eye, ear, nose, throat or mouth infection	<5 (NA%)	<5 (NA%)	<5 (NA%)	6 (1.6%)	<5 (NA%)	<5 (NA%)	<5 (NA%)	6 (0.2%)	23 (0.4%)	25 (0.4%)	15 (0.3%)	59 (1.3%)
Central nervous system infection		<5 (NA%)					17 (0.5%)	20 (0.6%)	37 (0.6%)	43 (0.7%)		
Catheter-related infection							14 (0.4%)	20 (0.6%)				
Cardiovascular system infection			<5 (NA%)	<5 (NA%)	<5 (NA%)	<5 (NA%)	19 (0.6%)	23 (0.7%)	113 (1.9%)	131 (2.2%)		
Bone and joint infection		<5 (NA%)	<5 (NA%)	5 (1.4%)	<5 (NA%)	<5 (NA%)	70 (2.2%)	92 (2.9%)	912 (15%)	1080 (17.8%)	<5 (NA%)	<5 (NA%)
Bloodstream infection	<5 (NA%)	11 (0.8%)			5 (0.6%)	6 (0.7%)	257 (8.1%)	444 (13.9%)	806 (13.3%)	1056 (17.4%)	40 (0.9%)	64 (1.4%)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1 Dissemination level: Public

TABLE 5– TOP 10 OF DISEASE CODES REPORTED AT TIME OF PRESCRIBING OF TOP 5 OF MOST PRESCRIBED ANTIBIOTICS PER DATABASE

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
azithromycin											
O/E - blood pressure reading	4395/130553 (3.4%)	Acute upper respiratory infection	15656/238132 (6.6%)	Acute lower respiratory tract infection	130479/1539019 (8.5%)	Essential hypertension	1179/19581 (6%)	Psychosocial problems related to unwanted pregnancy	200/3448 (5.8%)	Acute bronchitis	123171/674777 (18.3%)
C/O - cough	3098/130553 (2.4%)	Cough	13522/238132 (5.7%)	Acute pharyngitis	98562/1539019 (6.4%)	Infective pneumonia	1177/19581 (6%)	Legal termination of pregnancy without complication	144/3448 (4.2%)	Acute upper respiratory infection	101608/674777 (15.1%)
Lower respiratory tract infection	2685/130553 (2.1%)	Acute bronchitis	11574/238132 (4.9%)	Acute bronchitis	55851/1539019 (3.6%)	Hyperlipidemia	901/19581 (4.6%)	Essential hypertension	74/3448 (2.1%)	Bronchitis	66263/674777 (9.8%)
Cough	2594/130553 (2%)	Fear of contracting venereal disease	7896/238132 (3.3%)	Acute tonsillitis	55843/1539019 (3.6%)	Pneumonia	739/19581 (3.8%)	Fever	73/3448 (2.1%)	Acute pharyngitis	57601/674777 (8.5%)
Chlamydial infection	1900/130553 (1.5%)	Acute tonsillitis	7813/238132 (3.3%)	Common cold	53465/1539019 (3.5%)	Acute respiratory failure	685/19581 (3.5%)	Tobacco dependence syndrome	71/3448 (2.1%)	Acute tonsillitis	47538/674777 (7%)
O/E - pulse rate	1522/130553 (1.2%)	Chlamydial infection	7595/238132 (3.2%)	Cough	49215/1539019 (3.2%)	Type 2 diabetes mellitus without complication	632/19581 (3.2%)	Acute hypoxemic respiratory failure	64/3448 (1.9%)	Illness	33383/674777 (4.9%)
Upper respiratory infection	1401/130553 (1.1%)	Infection of vagina due to Chlamydia trachomatis	5837/238132 (2.5%)	Bronchitis	44334/1539019 (2.9%)	Viral pneumonia	624/19581 (3.2%)	Chlamydial infection of lower genitourinary tract	60/3448 (1.7%)	Chronic sinusitis	28601/674777 (4.2%)
Productive cough	1036/130553 (0.8%)	Pneumonia	5800/238132 (2.4%)	Acute upper respiratory infection	25221/1539019 (1.6%)	Disease due to Coronaviridae	617/19581 (3.2%)	Abdominal pain	58/3448 (1.7%)	Acute laryngitis	22347/674777 (3.3%)
Acute lower respiratory tract infection	1011/130553 (0.8%)	Acute rhinosinusitis	5673/238132 (2.4%)	Acute sinusitis	20082/1539019 (1.3%)	Acute renal failure syndrome	616/19581 (3.1%)	Nausea and vomiting	56/3448 (1.6%)	Cough	20898/674777 (3.1%)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
	Dissemination level: Public	

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Acute tonsillitis	741/ 130553 (0.6%)	Chronic obstructive lung disease	5544/ 238132 (2.3%)	Pneumonia	14377/ 1539019	Urethritis	597/19581 (3%)	Hypo-osmolality and or hyponatremia	52/3448 (1.5%)	Otitis media	20439/ 674777 (3%)
cefador											
O/E - blood pressure reading	1088/ 15857 (6.9%)	Urinary tract infectious disease	84/1125 (7.5%)	Disorder due to infection	480/4830 (9.9%)			Esophageal varices without bleeding	<5/107 (<3.7%)	Acute tonsillitis	62554/ 369117 (16.9%)
Lower respiratory tract infection	740/15857 (4.7%)	Chronic obstructive lung disease	57/1125 (5.1%)	Acute suppurative otitis media with spontaneous rupture of ear drum	206/4830 (4.3%)			Dysphagia	<5/107 (<3.7%)	Otitis media	43618/ 369117 (11.8%)
C/O - cough	726/15857 (4.6%)	Acute upper respiratory infection	42/1125 (3.7%)	Acute secretory otitis media	163/4830 (3.4%)			Scoliosis deformity of spine	<5/107 (<3.7%)	Acute upper respiratory infection	37669/ 369117 (10.2%)
Cough	526/15857 (3.3%)	Cough	39/1125 (3.5%)	Acute sinusitis	130/4830 (2.7%)			Arthropathy associated with a neurological disorder	<5/107 (<3.7%)	Acute bronchitis	35276/ 369117 (9.6%)
Urinary tract infectious disease	404/15857 (2.5%)	Acute bronchitis	30/1125 (2.7%)	Acute tonsillitis	128/4830 (2.7%)			Non-toxic multinodular goiter	<5/107 (<3.7%)	Acute pharyngitis	22858/ 369117 (6.2%)
O/E - pulse rate	396/15857 (2.5%)	Pneumonia	29/1125 (2.6%)	Impetigo	122/4830 (2.5%)			Toxic diffuse goiter	<5/107 (<3.7%)	Disorder due to infection	22559/ 369117 (6.1%)
Acute lower respiratory tract infection	360/15857 (2.3%)	Otitis media	26/1125 (2.3%)	Urinary tract infectious disease	107/4830 (2.2%)			Changes in skin texture	<5/107 (<3.7%)	Fever	21029/ 369117 (5.7%)
Upper respiratory infection	321/15857 (2%)	Cystitis	17/1125 (1.5%)	Otitis media	100/4830 (2.1%)			Gastroduodenitis	<5/107 (<3.7%)	Bronchitis	15981/ 369117 (4.3%)
Productive cough	280/15857 (1.8%)	Acute rhinosinusitis	11/1125 (1%)	Non-suppurative otitis media	73/4830 (1.5%)			Alcoholic cirrhosis	<5/107 (<3.7%)	Urinary tract infectious disease	11954/ 369117 (3.2%)
Abdominal pain	277/15857 (1.7%)	Acute tonsillitis	10/1125 (0.9%)	Cellulitis	64/4830 (1.3%)			Ulcer of lower extremity	<5/107 (<3.7%)	Streptococcal tonsillitis	11861/ 369117 (3.2%)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
	Dissemination level: Public	

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
ceftriaxone											
Cellulitis	168/992 (16.9%)	Gonorrhea	2723/4986 (54.6%)	Nongonococcal urethritis	2679/17680 (15.2%)	Urinary tract infectious disease	2756/22572 (12.2%)	Essential hypertension	8641/45936 (18.8%)	Lyme disease	531/2859 (18.6%)
O/E - blood pressure reading	44/992 (4.4%)	Fear of contracting venereal disease	664/4986 (13.3%)	Acute lower respiratory tract infection	1097/17680 (6.2%)	Essential hypertension	2649/22572 (11.7%)	Infection due to Escherichia coli	3433/45936 (7.5%)	Gonorrhea	315/2859 (11%)
O/E - pulse rate	26/992 (2.6%)	Chlamydial infection	182/4986 (3.7%)	Gonorrhea	1077/17680 (6.1%)	Hyperlipidemia	2025/22572 (9%)	Fever	3330/45936 (7.2%)	Pneumonia	74/2859 (2.6%)
Infection of skin and/or subcutaneous tissue	16/992 (1.6%)	Infection of vagina due to Chlamydia trachomatis	102/4986 (2%)	Urinary tract infectious disease	971/17680 (5.5%)	Acute renal failure syndrome	1776/22572 (7.9%)	Acute tubulointerstitial nephritis	3166/45936 (6.9%)	Acute bronchitis	72/2859 (2.5%)
Gonorrhea	16/992 (1.6%)	Discharge from penis	45/4986 (0.9%)	Disorder due to infection	299/17680 (1.7%)	Type 2 diabetes mellitus without complication	1487/22572 (6.6%)	Systemic inflammatory response syndrome without organ dysfunction	2987/45936 (6.5%)	Illness	65/2859 (2.3%)
Lower respiratory tract infection	15/992 (1.5%)	Chlamydial cervicitis	45/4986 (0.9%)	Sexually transmitted infectious disease	296/17680 (1.7%)	Infection due to Escherichia coli	1131/22572 (5%)	Disorientated	2687/45936 (5.8%)	Urinary tract infectious disease	55/2859 (1.9%)
Cellulitis of lower limb	15/992 (1.5%)	Urethritis	35/4986 (0.7%)	Pneumonia	278/17680 (1.6%)	Acute pyelonephritis without medullary necrosis	1093/22572 (4.8%)	Hypo-osmolality and or hyponatremia	2646/45936 (5.8%)	Urethritis	55/2859 (1.9%)
Cellulitis and abscess of lower limb	13/992 (1.3%)	Disorder of breast	33/4986 (0.7%)	Female pelvic inflammatory disease	234/17680 (1.3%)	Atrial fibrillation	998/22572 (4.4%)	Dyspnea	2545/45936 (5.5%)	Erysipelas	45/2859 (1.6%)
Acute lower respiratory tract infection	6/992 (0.6%)	Dysuria	32/4986 (0.6%)	Pneumonitis due to inhaled substance	192/17680 (1.1%)	Acute pyelonephritis	987/22572 (4.4%)	Hypokalemia	2502/45936 (5.4%)	Essential hypertension	43/2859 (1.5%)
Urinary tract infectious disease	5/992 (0.5%)	Disorder of male genital organ	27/4986 (0.5%)	Fever	153/17680 (0.9%)	Infective pneumonia	938/22572 (4.2%)	Anemia	2417/45936 (5.3%)	Acute upper respiratory infection	37/2859 (1.3%)
cefuroxime											



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
O/E - blood pressure reading	291/4640 (6.3%)	Urinary tract infectious disease	615/2345 (26.2%)	Urinary tract infectious disease	102141/576002 (17.7%)	Urinary tract infectious disease	18/3129 (0.6%)	Essential hypertension	159/1685 (9.4%)	Acute bronchitis	123744/929894 (13.3%)
Abdominal pain	202/4640 (4.4%)	Cystitis	153/2345 (6.5%)	Acute cystitis	11101/576002 (1.9%)	COVID-19	5/3129 (0.2%)	Fever	74/1685 (4.4%)	Acute upper respiratory infection	71393/929894 (7.7%)
Lower respiratory tract infection	130/4640 (2.8%)	Gonorrhea	38/2345 (1.6%)	Acute lower respiratory tract infection	9533/576002 (1.7%)	Acute tonsillitis	<5/3129 (<0.1%)	Acute posthemorrhagic anemia	69/1685 (4.1%)	Bronchitis	64279/929894 (6.9%)
Cough	123/4640 (2.7%)	Acute pyelitis	25/2345 (1.1%)	Acute pyelonephritis	7773/576002 (1.3%)	Pathological fracture of vertebra	<5/3129 (<0.1%)	Difficulty walking	66/1685 (3.9%)	Acute tonsillitis	59031/929894 (6.3%)
C/O - cough	105/4640 (2.3%)	Acute pyelonephritis	25/2345 (1.1%)	Acute sinusitis	7144/576002 (1.2%)	Genitourinary tract infection in pregnancy	<5/3129 (<0.1%)	Pure hypercholesterolemia	63/1685 (3.7%)	Urinary tract infectious disease	51512/929894 (5.5%)
O/E - pulse rate	100/4640 (2.2%)	Type 2 diabetes mellitus	22/2345 (0.9%)	Acute suppurative otitis media with spontaneous rupture of ear drum	5468/576002 (0.9%)	Orchitis and epididymitis	<5/3129 (<0.1%)	Nausea and vomiting	59/1685 (3.5%)	Acute pharyngitis	49393/929894 (5.3%)
Urinary tract infectious disease	56/4640 (1.2%)	Erysipelas	21/2345 (0.9%)	Acute tonsillitis	5366/576002 (0.9%)	Hematuria syndrome	<5/3129 (<0.1%)	Pain in lower limb	58/1685 (3.4%)	Illness	32298/929894 (3.5%)
Diverticulitis	55/4640 (1.2%)	Dysuria	19/2345 (0.8%)	Acute secretory otitis media	4734/576002 (0.8%)	Osteoporosis	<5/3129 (<0.1%)	Complication of surgical procedure	56/1685 (3.3%)	Chronic sinusitis	28345/929894 (3%)
Cellulitis	51/4640 (1.1%)	Acute bronchitis	15/2345 (0.6%)	Acute bronchitis	4698/576002 (0.8%)	Rheumatoid arthritis	<5/3129 (<0.1%)	Complication of procedure	54/1685 (3.2%)	Acute sinusitis	26572/929894 (2.9%)
Acute lower respiratory tract infection	50/4640 (1.1%)	Chronic obstructive lung disease	14/2345 (0.6%)	Dysuria	4084/576002 (0.7%)	Candidiasis of urogenital site	<5/3129 (<0.1%)	Hyperkalemia	48/1685 (2.8%)	Otitis media	24249/929894 (2.6%)
ciprofloxacin											
O/E - blood pressure reading	23760/369519 (6.4%)	Urinary tract infectious disease	49896/182025 (27.4%)	Urinary tract infectious disease	192895/1258448 (15.3%)	Essential hypertension	1604/30187 (5.3%)	Essential hypertension	759/8841 (8.6%)	Urinary tract infectious disease	177625/677383 (26.2%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Urinary tract infectious disease	12641/369519 (3.4%)	Cystitis	13730/182025 (7.5%)	Gastrointestinal infection	18610/1258448 (1.5%)	Hyperlipidemia	1168/30187 (3.9%)	Infection due to Pseudomonas aeruginosa	208/8841 (2.4%)	Cystitis	44065/677383 (6.5%)
O/E - pulse rate	7799/369519 (2.1%)	Acute pyelitis	5248/182025 (2.9%)	Acute cystitis	18485/1258448 (1.5%)	Urinary tract infectious disease	853/30187 (2.8%)	Fever	185/8841 (2.1%)	Acute bronchitis	31923/677383 (4.7%)
Pain in testicle	7439/369519 (2%)	Acute pyelonephritis	5248/182025 (2.9%)	Acute prostatitis	12979/1258448 (1%)	Type 2 diabetes mellitus without complication	833/30187 (2.8%)	Anemia	181/8841 (2%)	Acute cystitis	24684/677383 (3.6%)
Abdominal pain	6873/369519 (1.9%)	Prostatitis	3970/182025 (2.2%)	Dysuria	12299/1258448 (1%)	Inflammatory disorder of digestive tract	624/30187 (2.1%)	Tobacco dependence in remission	177/8841 (2%)	Diverticular disease	19050/677383 (2.8%)
Acute epididymitis	5360/369519 (1.5%)	Dysuria	2577/182025 (1.4%)	Cellulitis	11402/1258448 (0.9%)	Acute renal failure syndrome	478/30187 (1.6%)	Pure hypercholesterolemia	174/8841 (2%)	Essential hypertension	18605/677383 (2.7%)
Dysuria	4962/369519 (1.3%)	Urgent desire to urinate	2544/182025 (1.4%)	Acute lower respiratory tract infection	11072/1258448 (0.9%)	Atrial fibrillation	432/30187 (1.4%)	Bacterial infectious disease	167/8841 (1.9%)	Bronchitis	17696/677383 (2.6%)
Cystitis	4575/369519 (1.2%)	Increased frequency of urination	2544/182025 (1.4%)	Orchitis and epididymitis	10340/1258448 (0.8%)	Atherosclerosis of arteries of the extremities	375/30187 (1.2%)	Acquired absence of organ	167/8841 (1.9%)	Acute upper respiratory infection	17260/677383 (2.5%)
Lower respiratory tract infection	4503/369519 (1.2%)	Difficulty passing urine	2298/182025 (1.3%)	Otitis externa	9868/1258448 (0.8%)	Chronic obstructive lung disease	364/30187 (1.2%)	Localized edema	164/8841 (1.9%)	Tubulointerstitial nephritis	13116/677383 (1.9%)
Diarrhea symptom	4297/369519 (1.2%)	Epididymitis	2280/182025 (1.3%)	Traumatic AND/OR non-traumatic injury	9041/1258448 (0.7%)	Tobacco dependence syndrome	346/30187 (1.1%)	Nausea and vomiting	162/8841 (1.8%)	Diverticulosis of large intestine without diverticulitis	12783/677383 (1.9%)
clarithromycin											
O/E - blood pressure reading	92473/1288110 (7.2%)	Acute bronchitis	5024/103009 (4.9%)	Helicobacter-associated disease	109338/488454 (22.4%)	Helicobacter-associated disease	5/1990 (0.3%)	Fever	43/821 (5.2%)	Acute bronchitis	59726/329386 (18.1%)
Cough	87141/1288110 (6.8%)	Cough	4647/103009 (4.5%)	Acute lower respiratory tract infection	26081/488454 (5.3%)	Esophagitis	<5/1990 (<0.2%)	Acute severe refractory exacerbation of asthma	43/821 (5.2%)	Bronchitis	31761/329386 (9.6%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Lower respiratory tract infection	82419/1288110 (6.4%)	Acute upper respiratory infection	4272/103009 (4.1%)	Acute tonsillitis	16471/488454 (3.4%)	Dysphagia	<5/1990 (<0.2%)	Acute hypoxemic respiratory failure	43/821 (5.2%)	Acute upper respiratory infection	31291/329386 (9.5%)
C/O - cough	76966/1288110 (6%)	Stomach ache	3760/103009 (3.7%)	Acute bronchitis	12340/488454 (2.5%)	Restless legs	<5/1990 (<0.2%)	Dyspnea	40/821 (4.9%)	Bacterial infectious disease	23100/329386 (7%)
Acute lower respiratory tract infection	45604/1288110 (3.5%)	Impetigo	3513/103009 (3.4%)	Acute sinusitis	8886/488454 (1.8%)	Inflammatory polyarthropathy	<5/1990 (<0.2%)	Essential hypertension	40/821 (4.9%)	Gastritis	21127/329386 (6.4%)
O/E - pulse rate	42079/1288110 (3.3%)	Pneumonia	3416/103009 (3.3%)	Acute pharyngitis	7710/488454 (1.6%)	Constipation	<5/1990 (<0.2%)	Pulmonary disease due to Mycobacteria	35/821 (4.3%)	Acute pharyngitis	19001/329386 (5.8%)
Acute tonsillitis	33878/1288110 (2.6%)	Erysipelas	3016/103009 (2.9%)	Cough	6395/488454 (1.3%)	Disorder of shoulder	<5/1990 (<0.2%)	Asthma	33/821 (4%)	Acute tonsillitis	17666/329386 (5.4%)
Sore throat symptom	29597/1288110 (2.3%)	Peptic ulcer	1931/103009 (1.9%)	Bronchitis	6393/488454 (1.3%)	Muscle atrophy	<5/1990 (<0.2%)	Pneumonia	32/821 (3.9%)	Illness	11141/329386 (3.4%)
Upper respiratory infection	28845/1288110 (2.2%)	Acute rhinosinusitis	1901/103009 (1.8%)	Pneumonia	5308/488454 (1.1%)	Cachexia	<5/1990 (<0.2%)	Lobar pneumonia	29/821 (3.5%)	Acute sinusitis	10198/329386 (3.1%)
Productive cough	20742/1288110 (1.6%)	Sinusitis	1887/103009 (1.8%)	Chronic gastritis	5246/488454 (1.1%)	Acquired hypothyroidism	<5/1990 (<0.2%)	Hypo-osmolality and or hyponatremia	24/821 (2.9%)	Pneumonia	9577/329386 (2.9%)
erythromycin											
O/E - blood pressure reading	35989/747601 (4.8%)	Acne	754/13733 (5.5%)	Acute tonsillitis	3439/56581 (6.1%)	Acute posthemorrhagic anemia	426/2169 (19.6%)	Essential hypertension	332/2973 (11.2%)	Acute bronchitis	18762/136769 (13.7%)
Acute tonsillitis	35603/747601 (4.8%)	Acute upper respiratory infection	489/13733 (3.6%)	Periapical abscess	1811/56581 (3.2%)	Gastrointestinal hemorrhage	266/2169 (12.3%)	Nausea and vomiting	196/2973 (6.6%)	Acne vulgaris	13125/136769 (9.6%)
C/O - cough	32539/747601 (4.4%)	Acute tonsillitis	361/13733 (2.6%)	Acute lower respiratory tract infection	1649/56581 (2.9%)	Essential hypertension	166/2169 (7.7%)	Complication of surgical procedure	130/2973 (4.4%)	Acute upper respiratory infection	10472/136769 (7.7%)
Cough	31856/747601 (4.3%)	Otitis media	335/13733 (2.4%)	Disorder of teeth AND/OR	1466/56581 (2.6%)	Hematemesis	147/2169 (6.8%)	Complication of procedure	126/2973 (4.2%)	Acne	8004/136769 (5.9%)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1 Dissemination level: Public

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
				supporting structures							
Sore throat symptom	27736/747601 (3.7%)	Cough	331/13733 (2.4%)	Acute pharyngitis	1294/56581 (2.3%)	Hematochezia	103/2169 (4.7%)	Disorder of upper gastrointestinal tract	109/2973 (3.7%)	Acute tonsillitis	7557/136769 (5.5%)
Upper respiratory infection	22761/747601 (3%)	Erysipelas	316/13733 (2.3%)	Acute bronchitis	760/56581 (1.3%)	Alcoholic cirrhosis	98/2169 (4.5%)	Malignant adenomatous neoplasm	106/2973 (3.6%)	Fever	6972/136769 (5.1%)
Lower respiratory tract infection	21964/747601 (2.9%)	Acute bronchitis	291/13733 (2.1%)	Abscess of skin and/or subcutaneous tissue	704/56581 (1.2%)	Portal hypertension	94/2169 (4.3%)	Retinopathy due to diabetes mellitus	105/2973 (3.5%)	Pneumonia	6235/136769 (4.6%)
Acne	19629/747601 (2.6%)	Pneumonia	278/13733 (2%)	Traumatic AND/OR non-traumatic injury	684/56581 (1.2%)	Type 2 diabetes mellitus without complication	87/2169 (4%)	Acute posthemorrhagic anemia	103/2973 (3.5%)	Bronchopneumonia	5254/136769 (3.8%)
O/E - pulse rate	13310/747601 (1.8%)	Mastitis associated with lactation	229/13733 (1.7%)	Streptococcal tonsillitis	662/56581 (1.2%)	Hyperlipidemia	84/2169 (3.9%)	Acquired absence of organ	95/2973 (3.2%)	Hair follicle disorder	5195/136769 (3.8%)
Acute lower respiratory tract infection	12557/747601 (1.7%)	Impetigo	172/13733 (1.3%)	Acute sinusitis	656/56581 (1.2%)	Diaphragmatic hernia	83/2169 (3.8%)	Hypokalemia	92/2973 (3.1%)	Bronchitis	5191/136769 (3.8%)
fosfomycin											
Urinary tract infectious disease	603/11222 (5.4%)	Urinary tract infectious disease	59182/147933 (40%)	Urinary tract infectious disease	767141/1896813 (40.4%)	Urinary tract infectious disease	799/19260 (4.1%)	Essential hypertension	51/1157 (4.4%)	Urinary tract infectious disease	180096/404127 (44.6%)
O/E - blood pressure reading	447/11222 (4%)	Cystitis	17901/147933 (12.1%)	Acute cystitis	159787/1896813 (8.4%)	Essential hypertension	230/19260 (1.2%)	Acute cystitis	36/1157 (3.1%)	Cystitis	69346/404127 (17.2%)
Recurrent urinary tract infection	310/11222 (2.8%)	Dysuria	2681/147933 (1.8%)	Dysuria	84925/1896813 (4.5%)	Hyperlipidemia	167/19260 (0.9%)	Infection due to Escherichia coli	29/1157 (2.5%)	Acute cystitis	35033/404127 (8.7%)
Cystitis	263/11222 (2.3%)	Urgent desire to urinate	2680/147933 (1.8%)	Abdominal pain	13757/1896813 (0.7%)	Retention of urine	163/19260 (0.8%)	Headache	28/1157 (2.4%)	Lower abdominal pain	10898/404127 (2.7%)
O/E - pulse rate	179/11222 (1.6%)	Increased frequency of urination	2680/147933 (1.8%)	Renal colic	12728/1896813 (0.7%)	Acute cystitis	142/19260 (0.7%)	Inflammatory disorder of head	24/1157 (2.1%)	Dysuria	10320/404127 (2.6%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Urinary symptoms	136/11222 (1.2%)	Difficulty passing urine	2098/147933 (1.4%)	Low back pain	7048/1896813 (0.4%)	Type 2 diabetes mellitus without complication	140/19260 (0.7%)	Urinary tract infectious disease	22/1157 (1.9%)	Illness	9817/404127 (2.4%)
Dysuria	131/11222 (1.2%)	Localized abdominal pain	946/147933 (0.6%)	Candida infection of genital region	6529/1896813 (0.3%)	Atrial fibrillation	116/19260 (0.6%)	Constipation	20/1157 (1.7%)	Essential hypertension	7808/404127 (1.9%)
C/O: a general symptom	56/11222 (0.5%)	Type 2 diabetes mellitus	820/147933 (0.6%)	Hematuria syndrome	5971/1896813 (0.3%)	Hematuria syndrome	113/19260 (0.6%)	Hypokalemia	20/1157 (1.7%)	Hematuria syndrome	7283/404127 (1.8%)
Increased frequency of urination	52/11222 (0.5%)	Essential hypertension	732/147933 (0.5%)	Acute vaginitis	4895/1896813 (0.3%)	Delirium	106/19260 (0.6%)	Finding related to pregnancy	19/1157 (1.6%)	Noninflammatory disorder of the vagina	7122/404127 (1.8%)
Abdominal pain	33/11222 (0.3%)	Urine finding	731/147933 (0.5%)	Common cold	4052/1896813 (0.2%)	Acute renal failure syndrome	101/19260 (0.5%)	Disorientated	19/1157 (1.6%)	Acute vaginitis	5195/404127 (1.3%)
levofloxacin											
O/E - blood pressure reading	696/10593 (6.6%)	Epididymitis	1952/9873 (19.8%)	Acute lower respiratory tract infection	122397/891616 (13.7%)	Essential hypertension	1964/29141 (6.7%)	Essential hypertension	786/6054 (13%)	Acute bronchitis	32166/224573 (14.3%)
Lower respiratory tract infection	515/10593 (4.9%)	Inflammatory disorder of male genital organ	838/9873 (8.5%)	Acute bronchitis	44698/891616 (5%)	Acute bronchitis	1832/29141 (6.3%)	Cataract	290/6054 (4.8%)	Urinary tract infectious disease	26363/224573 (11.7%)
O/E - pulse rate	341/10593 (3.2%)	Pain in male genitalia	313/9873 (3.2%)	Pneumonia	30421/891616 (3.4%)	Acute exacerbation of chronic obstructive bronchitis	1610/29141 (5.5%)	Senile cataract	264/6054 (4.4%)	Bronchitis	17718/224573 (7.9%)
Cough	332/10593 (3.1%)	Male genitalia finding	286/9873 (2.9%)	Bronchitis	20079/891616 (2.3%)	Hyperlipidemia	1505/29141 (5.2%)	Complication of surgical procedure	205/6054 (3.4%)	Acute upper respiratory infection	11047/224573 (4.9%)
C/O - cough	330/10593 (3.1%)	Urinary tract infectious disease	214/9873 (2.2%)	Cough	12193/891616 (1.4%)	Acute respiratory failure	1503/29141 (5.2%)	Type 2 diabetes mellitus	193/6054 (3.2%)	Chronic obstructive lung disease	6828/224573 (3%)
Acute lower respiratory tract infection	253/10593 (2.4%)	Localized abdominal pain	114/9873 (1.2%)	Urinary tract infectious disease	9292/891616 (1%)	Infective pneumonia	1454/29141 (5%)	Pure hypercholesterolemia	178/6054 (2.9%)	Essential hypertension	6582/224573 (2.9%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Pain in testicle	147/10593 (1.4%)	Prostatitis	109/9873 (1.1%)	Fever	7287/ 891616 (0.8%)	Disorder of respiratory system	1299/ 29141 (4.5%)	Corneal ulcer	130/6054 (2.1%)	Cystitis	6515/ 224573 (2.9%)
Acute epididymitis	139/10593 (1.3%)	Chronic obstructive lung disease	107/9873 (1.1%)	Acute sinusitis	7101/ 891616 (0.8%)	Atrial fibrillation	1123/ 29141 (3.9%)	Penetrating wound of eyeball without foreign body	130/6054 (2.1%)	Pneumonia	5637/ 224573 (2.5%)
Prostatitis	136/10593 (1.3%)	Pneumonia	95/9873 (1%)	Common cold	5982/ 891616 (0.7%)	Type 2 diabetes mellitus without complication	1063/ 29141 (3.6%)	Bacterial pneumonia	122/6054 (2%)	Chronic sinusitis	4548/ 224573 (2%)
Acute exacerbation of chronic obstructive airways disease	129/10593 (1.2%)	Cough	85/9873 (0.9%)	Helicobacter-associated disease	5362/ 891616 (0.6%)	Acute renal failure syndrome	828/29141 (2.8%)	Atrial arrhythmia	122/6054 (2%)	Acute cystitis	4517/ 224573 (2%)
lymecycline											
Acne	84084/ 313052 (26.9%)							Enthesopathy	<5/54 (<7.4%)		
Rosacea	16018/ 313052 (5.1%)							Primary malignant neoplasm of rectum	<5/54 (<7.4%)		
O/E - blood pressure reading	14620/ 313052 (4.7%)							Constipation	<5/54 (<7.4%)		
Folliculitis	4613/ 313052 (1.5%)							Osteoporosis	<5/54 (<7.4%)		
C/O: a rash	3997/ 313052 (1.3%)							Lipodystrophy	<5/54 (<7.4%)		
Perioral dermatitis	1646/ 313052 (0.5%)							Hirsutism	<5/54 (<7.4%)		
Eruption	1421/ 313052 (0.5%)							Pressure ulcer	<5/54 (<7.4%)		



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Hidradenitis suppurativa	1406/313052 (0.4%)							Rosacea	<5/54 (<7.4%)		
Depressed mood	1160/313052 (0.4%)							Disorder of muscle	<5/54 (<7.4%)		
Hidradenitis	1141/313052 (0.4%)							Postoperative hypothyroidism	<5/54 (<7.4%)		
ofloxacin											
Pain in testicle	1447/26405 (5.5%)	Female pelvic inflammatory disease	646/6413 (10.1%)	Urinary tract infectious disease	214/2505 (8.5%)			Essential hypertension	689/9350 (7.4%)	Conjunctivitis	46483/173681 (26.8%)
O/E - blood pressure reading	1441/26405 (5.5%)	Urinary tract infectious disease	465/6413 (7.3%)	Nongonococcal urethritis	90/2505 (3.6%)			Infection due to Escherichia coli	216/9350 (2.3%)	Mucopurulent conjunctivitis	29165/173681 (16.8%)
Acute epididymitis	1082/26405 (4.1%)	Epididymitis	333/6413 (5.2%)	Orchitis and epididymitis	76/2505 (3%)			Urinary tract infectious disease	201/9350 (2.1%)	Urinary tract infectious disease	16274/173681 (9.4%)
Abdominal pain	969/26405 (3.7%)	Localized abdominal pain	235/6413 (3.7%)	Dysuria	34/2505 (1.4%)			Pure hypercholesterolemia	187/9350 (2%)	Acute upper respiratory infection	14012/173681 (8.1%)
Orchitis and epididymitis	890/26405 (3.4%)	Prostatitis	209/6413 (3.3%)	Acute prostatitis	30/2505 (1.2%)			Atherosclerosis of arteries of the extremities	181/9350 (1.9%)	Acute conjunctivitis	7548/173681 (4.3%)
C/O pelvic pain	791/26405 (3%)	Inflammatory disorder of male genital organ	170/6413 (2.7%)	Acute cystitis	28/2505 (1.1%)			Fever	170/9350 (1.8%)	Cystitis	7099/173681 (4.1%)
Epididymitis	673/26405 (2.5%)	Cystitis	125/6413 (1.9%)	Female pelvic inflammatory disease	25/2505 (1%)			Acute tubulointerstitial nephritis	162/9350 (1.7%)	Otitis media	4023/173681 (2.3%)
Prostatitis	650/26405 (2.5%)	Chlamydial pelvic inflammatory disease	101/6413 (1.6%)	Prostatitis	20/2505 (0.8%)			Nausea and vomiting	161/9350 (1.7%)	Acute bronchitis	4007/173681 (2.3%)
Orchitis	480/26405 (1.8%)	Generalized abdominal pain	70/6413 (1.1%)	Acute lower respiratory tract infection	17/2505 (0.7%)			Atrial arrhythmia	154/9350 (1.6%)	Acute cystitis	3753/173681 (2.2%)



Study Report for C1-003 - Appendix

Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier

Version: v3.1

Dissemination level: Public

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
O/E - pulse rate	469/26405 (1.8%)	Stomach cramps	70/6413 (1.1%)	Abdominal pain	15/2505 (0.6%)			Bacterial infectious disease	145/9350 (1.6%)	Blepharitis	3581/ 173681 (2.1%)
oxytetracycline											
Acne	22348/ 187002 (12%)	Otitis externa	2513/ 17755 (14.2%)	External hordeolum	13108/ 51425 (25.5%)	Acute periodontitis	<5/201 (<2%)				
Rosacea	11658/ 187002 (6.2%)	Otitis media	453/17755 (2.6%)	Blepharitis	3816/ 51425 (7.4%)						
O/E - blood pressure reading	9087/ 187002 (4.9%)	Ear discharge	335/17755 (1.9%)	Conjunctivitis	1212/ 51425 (2.4%)						
C/O - cough	3043/ 187002 (1.6%)	Otalgia	255/17755 (1.4%)	Acute conjunctivitis	1102/ 51425 (2.1%)						
C/O: a rash	2149/ 187002 (1.1%)	Excessive cerumen in ear canal	138/17755 (0.8%)	Chalazion	798/51425 (1.6%)						
Lower respiratory tract infection	1964/ 187002 (1.1%)	Serous otitis media	136/17755 (0.8%)	Disorder of eye region	734/51425 (1.4%)						
Cough	1891/ 187002 (1%)	Essential hypertension	103/17755 (0.6%)	Inflammatory dermatosis	434/51425 (0.8%)						
Folliculitis	1737/ 187002 (0.9%)	Chronic otitis media	84/17755 (0.5%)	Mucopurulent conjunctivitis	367/51425 (0.7%)						
Upper respiratory infection	1725/ 187002 (0.9%)	Eczema	82/17755 (0.5%)	Balanitis	258/51425 (0.5%)						
Acute sinusitis	1199/ 187002 (0.6%)	Type 2 diabetes mellitus	72/17755 (0.4%)	Traumatic AND/OR non-traumatic injury	255/51425 (0.5%)						
pheneticillin											

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
	Dissemination level: Public	

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
		Acute tonsillitis	29364/ 65261 (45%)								
		Peritonsillar abscess	11944/ 65261 (18.3%)								
		Pain in throat	6027/ 65261 (9.2%)								
		Pharyngeal finding	5267/ 65261 (8.1%)								
		Acute pharyngitis	3667/ 65261 (5.6%)								
		Streptococcal infectious disease	2488/ 65261 (3.8%)								
		Tonsil finding	2171/ 65261 (3.3%)								
		Acute upper respiratory infection	2098/ 65261 (3.2%)								
		Streptococcal sore throat	1043/ 65261 (1.6%)								
		Erysipelas	771/ 65261 (1.2%)								
Piperacillin_tazobactam											
Lower respiratory tract infection	6/119 (5%)	Disorder due to infection	<5/29 (<13.8%)					Essential hypertension	3725/ 23834 (15.6%)	Pneumonia	11/108 (10.2%)
O/E - blood pressure reading	5/119 (4.2%)	Boil of external nose	<5/29 (<13.8%)					Complication of surgical procedure	1699/ 23834 (7.1%)	Tetraplegia	<5/108 (<3.7%)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
	Dissemination level: Public	

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Gastro-esophageal reflux disease with esophagitis	<5/119 (<3.4%)	Congenital malformation of the respiratory system	<5/29 (<13.8%)					Hypokalemia	1496/23834 (6.3%)	Fever	<5/108 (<3.7%)
Urinary tract infectious disease	<5/119 (<3.4%)	Abscess of nose	<5/29 (<13.8%)					Hypo-osmolality and or hyponatremia	1338/23834 (5.6%)	Motor neuron disease	<5/108 (<3.7%)
Bacteremia	<5/119 (<3.4%)							Fever	1337/23834 (5.6%)	Urinary incontinence	<5/108 (<3.7%)
Chronic ulcer of skin	<5/119 (<3.4%)							Complication of procedure	1238/23834 (5.2%)	Open wound of anterior abdominal wall	<5/108 (<3.7%)
Low back pain	<5/119 (<3.4%)							Bacterial infectious disease	1236/23834 (5.2%)	Secondary malignant neoplasm of bone	<5/108 (<3.7%)
Cystitis	<5/119 (<3.4%)							Anemia	1160/23834 (4.9%)	Disorder of soft tissue	<5/108 (<3.7%)
Cough	<5/119 (<3.4%)							Infection due to Escherichia coli	1127/23834 (4.7%)	Disorder of intestine	<5/108 (<3.7%)
Chronic obstructive lung disease	<5/119 (<3.4%)							Tobacco dependence in remission	1126/23834 (4.7%)	Acute gastritis	<5/108 (<3.7%)
vancomycin											
Clostridioides difficile infection	143/1360 (10.5%)	Diarrheal disorder	39/559 (7%)	Clostridium difficile colitis	56/896 (6.2%)	Essential hypertension	317/3893 (8.1%)	Interstitial keratitis	717/6105 (11.7%)	Clostridioides difficile infection	1239/4519 (27.4%)
Diarrhea symptom	106/1360 (7.8%)	Infectious diarrheal disease	17/559 (3%)	Infection due to Clostridium perfringens	42/896 (4.7%)	Hyperlipidemia	221/3893 (5.7%)	Essential hypertension	683/6105 (11.2%)	Bacterial enteritis	486/4519 (10.8%)
O/E - blood pressure reading	76/1360 (5.6%)	Gastroenteritis presumed infectious	13/559 (2.3%)	Bacterial enteritis	32/896 (3.6%)	Type 2 diabetes mellitus without complication	132/3893 (3.4%)	Complication of surgical procedure	499/6105 (8.2%)	Inflammatory disorder of digestive tract	307/4519 (6.8%)
O/E - pulse rate	33/1360 (2.4%)	Urinary tract infectious disease	5/559 (0.9%)	Clostridioides difficile infection	30/896 (3.3%)	Osteoarthritis of knee	118/3893 (3%)	Corneal ulcer	330/6105 (5.4%)	Essential hypertension	240/4519 (5.3%)

	Study Report for C1-003 - Appendix	
	Author(s): Katia Verhamme, Maria de Ridder, Talita Duarte Salles, Dani Prieto Alhambra, Miguel-Angel Mayer, Romain Griffier	Version: v3.1
	Dissemination level: Public	

CPRD GOLD		IPCI		SIDIAP		IMASIS		CHUBX		IQVIA Germany	
Diarrhea	32/1360 (2.4%)	Disorder of esophagus	<5/559 (<0.7%)	Disorder of intestine	16/896 (1.8%)	Obesity	61/3893 (1.6%)	Pain in eye	308/6105 (5%)	Illness	121/4519 (2.7%)
Clostridial infection	19/1360 (1.4%)	Disorder of endocrine system	<5/559 (<0.7%)	Gastrointestinal infection	14/896 (1.6%)	Depressive disorder	61/3893 (1.6%)	Bacterial infectious disease	284/6105 (4.7%)	Disorder of intestine	89/4519 (2%)
Abdominal pain	17/1360 (1.2%)	Finding of hand region	<5/559 (<0.7%)	Diarrhea	10/896 (1.1%)	Clostridioides difficile infection	60/3893 (1.5%)	Staphylococcal infectious disease	281/6105 (4.6%)	Gas gangrene	87/4519 (1.9%)
Clostridium difficile toxin A detected	9/1360 (0.7%)	Breast lump	<5/559 (<0.7%)	Disorder due to infection	10/896 (1.1%)	Acquired hallux valgus	59/3893 (1.5%)	Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft	273/6105 (4.5%)	Urinary tract infectious disease	81/4519 (1.8%)
Patient condition unchanged	5/1360 (0.4%)	Candidiasis of urogenital site	<5/559 (<0.7%)	Indeterminate colitis	10/896 (1.1%)	Complication of surgical procedure	57/3893 (1.5%)	Infection due to Staphylococcus aureus	263/6105 (4.3%)	Hypokalemia	57/4519 (1.3%)
Candidiasis of mouth	<5/1360 (<0.3%)	Ulcerative colitis	<5/559 (<0.7%)	Urinary tract infectious disease	5/896 (0.6%)	Atrial fibrillation	53/3893 (1.4%)	Complication of procedure	255/6105 (4.2%)	Heart failure	50/4519 (1.1%)